Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 293
2021 966
2022 1277
2023 104
Text availability
Article attribute
Article type
Publication date

Search Results

1,216 results
Results by year
Filters applied: in the last 1 year. Clear all
Page 1
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.
Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, Moustafa Abo El-Ella D, Bedhiafi T, Raza A, Al-Zaidan L, Mohsen MO, Yousuf Al-Nesf MA, Hssain AA, Yassine HM, Bachmann MF, Uddin S, Dermime S. Fernandes Q, et al. Ann Med. 2022 Dec;54(1):524-540. doi: 10.1080/07853890.2022.2031274. Ann Med. 2022. PMID: 35132910 Free PMC article. Review.
In addition, we also discuss the development, formulation, working mechanisms, advantages, and drawbacks of some of the most used vaccines/therapeutic drugs and their subsequent immunological impact.Key messageThe emergence of novel variants of the SARS-CoV-2 in the past couple o …
In addition, we also discuss the development, formulation, working mechanisms, advantages, and drawbacks of some of the most used vaccines/t …
COVID-19 mRNA vaccines: Platforms and current developments.
Szabó GT, Mahiny AJ, Vlatkovic I. Szabó GT, et al. Mol Ther. 2022 May 4;30(5):1850-1868. doi: 10.1016/j.ymthe.2022.02.016. Epub 2022 Feb 19. Mol Ther. 2022. PMID: 35189345 Free PMC article. Review.
This research uncovered the unique favorable characteristics of mRNA vaccines, including their ability to give rise to non-toxic, potent immune responses and the potential to design and upscale them rapidly, making them excellent vaccine candidates during the coronavirus d …
This research uncovered the unique favorable characteristics of mRNA vaccines, including their ability to give rise to non-toxic, potent imm …
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
Thomas SJ, Perez JL, Lockhart SP, Hariharan S, Kitchin N, Bailey R, Liau K, Lagkadinou E, Türeci Ö, Şahin U, Xu X, Koury K, Dychter SS, Lu C, Gentile TC, Gruber WC. Thomas SJ, et al. Vaccine. 2022 Mar 1;40(10):1483-1492. doi: 10.1016/j.vaccine.2021.12.046. Epub 2021 Dec 24. Vaccine. 2022. PMID: 35131133 Free PMC article. Clinical Trial.
INTRODUCTION: Individuals with an underlying malignancy have high risk of poor COVID-19 outcomes. In clinical trials, COVID-19 vaccines were safe and efficacious against infection, hospitalization, and death, but most trials excluded participants with cancer. …
INTRODUCTION: Individuals with an underlying malignancy have high risk of poor COVID-19 outcomes. In clinical trials, COVID-19 …
Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study.
Yasin AI, Aydin SG, Sümbül B, Koral L, Şimşek M, Geredeli Ç, Öztürk A, Perkin P, Demirtaş D, Erdemoglu E, Hacıbekiroglu İ, Çakır E, Tanrıkulu E, Çoban E, Ozcelik M, Çelik S, Teker F, Aksoy A, Fırat ST, Tekin Ö, Kalkan Z, Türken O, Oven BB, Dane F, Bilici A, Isıkdogan A, Seker M, Türk HM, Gümüş M. Yasin AI, et al. Future Oncol. 2022 Mar;18(10):1235-1244. doi: 10.2217/fon-2021-1248. Epub 2022 Jan 27. Future Oncol. 2022. PMID: 35081732 Free PMC article.

Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. ...These results highlight the importance of determinin

Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.
Fendler A, de Vries EGE, GeurtsvanKessel CH, Haanen JB, Wörmann B, Turajlic S, von Lilienfeld-Toal M. Fendler A, et al. Nat Rev Clin Oncol. 2022 Jun;19(6):385-401. doi: 10.1038/s41571-022-00610-8. Epub 2022 Mar 11. Nat Rev Clin Oncol. 2022. PMID: 35277694 Free PMC article. Review.
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. ...In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became av …
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general pop …
COVID-19 vaccine acceptance and hesitancy among patients with cancer: a systematic review and meta-analysis.
Prabani KIP, Weerasekara I, Damayanthi HDWT. Prabani KIP, et al. Public Health. 2022 Nov;212:66-75. doi: 10.1016/j.puhe.2022.09.001. Epub 2022 Sep 8. Public Health. 2022. PMID: 36244261 Free PMC article. Review.
This study aims to investigate COVID-19 vaccine acceptance and hesitancy among patients with cancer. ...Female gender and undergoing active anticancer treatments were significant factors associated with COVID-19 vaccine hesitancy. Early cance
This study aims to investigate COVID-19 vaccine acceptance and hesitancy among patients with cancer. ...Female gender a …
Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.
Lorentzen CL, Haanen JB, Met Ö, Svane IM. Lorentzen CL, et al. Lancet Oncol. 2022 Oct;23(10):e450-e458. doi: 10.1016/S1470-2045(22)00372-2. Lancet Oncol. 2022. PMID: 36174631 Free PMC article. Review.
Therapeutic cancer vaccines based on mRNA are well tolerated, and the inherent advantage in ease of production, which rivals the best available conventional vaccine manufacture methods, renders mRNA vaccines a promising option for cancer immunotherapy. Techno …
Therapeutic cancer vaccines based on mRNA are well tolerated, and the inherent advantage in ease of production, which rivals the best …
Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.
Zinatizadeh MR, Zarandi PK, Zinatizadeh M, Yousefi MH, Amani J, Rezaei N. Zinatizadeh MR, et al. Biomed Pharmacother. 2022 Feb;146:112527. doi: 10.1016/j.biopha.2021.112527. Epub 2021 Dec 10. Biomed Pharmacother. 2022. PMID: 34906769 Free PMC article. Review.
The third major cause of mortality in the United States, following heart disease and cancer in 2020, was undoubtedly COVID-19. The centers for disease control and prevention (CDC) and the world health organization (WHO) separately developed a categorization system f …
The third major cause of mortality in the United States, following heart disease and cancer in 2020, was undoubtedly COVID-19. …
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.
Galmiche S, Luong Nguyen LB, Tartour E, de Lamballerie X, Wittkop L, Loubet P, Launay O. Galmiche S, et al. Clin Microbiol Infect. 2022 Feb;28(2):163-177. doi: 10.1016/j.cmi.2021.09.036. Epub 2021 Nov 17. Clin Microbiol Infect. 2022. PMID: 35020589 Free PMC article. Review.
BACKGROUND: Available data show that COVID-19 vaccines may be less effective in immunocompromised populations, who are at increased risk of severe COVID-19. ...Despite lack of vaccine effectiveness data, enhanced vaccine regimens may be necessary....
BACKGROUND: Available data show that COVID-19 vaccines may be less effective in immunocompromised populations, who are at increased r …
mRNA cancer vaccines: Advances, trends and challenges.
He Q, Gao H, Tan D, Zhang H, Wang JZ. He Q, et al. Acta Pharm Sin B. 2022 Jul;12(7):2969-2989. doi: 10.1016/j.apsb.2022.03.011. Epub 2022 Mar 23. Acta Pharm Sin B. 2022. PMID: 35345451 Free PMC article. Review.
Food and Drug Administration (FDA) approved the first mRNA-based coronavirus disease 2019 (COVID-19) vaccine produced by Pfizer and BioNTech, which has generated enthusiasm for mRNA vaccine research and development. Based on the above characteristics and the …
Food and Drug Administration (FDA) approved the first mRNA-based coronavirus disease 2019 (COVID-19) vaccine produced by Pfize …
COVID-19 vaccine response and safety in patients with cancer: An overview of systematic reviews.
Sun H, Bu F, Li L, Zhang X, Yan J, Huang T. Sun H, et al. Front Public Health. 2022 Nov 15;10:1072137. doi: 10.3389/fpubh.2022.1072137. eCollection 2022. Front Public Health. 2022. PMID: 36457318 Free PMC article.
There are still some doubts about efficacy and safety of the COVID-19 vaccine in cancer patients. PURPOSE: To identify, summarize and synthesize the available evidence of systematic reviews on response and COVID-19 vaccine safety in patients wit …
There are still some doubts about efficacy and safety of the COVID-19 vaccine in cancer patients. PURPOSE: To identify, …
Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative.
Song Q, Bates B, Shao YR, Hsu FC, Liu F, Madhira V, Mitra AK, Bergquist T, Kavuluru R, Li X, Sharafeldin N, Su J, Topaloglu U. Song Q, et al. J Clin Oncol. 2022 May 1;40(13):1414-1427. doi: 10.1200/JCO.21.02419. Epub 2022 Mar 14. J Clin Oncol. 2022. PMID: 35286152 Free PMC article.
PURPOSE: To provide real-world evidence on risks and outcomes of breakthrough COVID-19 infections in vaccinated patients with cancer using the largest national cohort of COVID-19 cases and controls. METHODS: We used the National COVID Cohort Collaborat …
PURPOSE: To provide real-world evidence on risks and outcomes of breakthrough COVID-19 infections in vaccinated patients with canc
Cancer vaccines.
Schiller JT, Lowy DR, Frazer IH, Finn OJ, Vilar E, Lyerly HK, Gnjatic S, Zaidi N, Ott PA, Balachandran VP, Dietrich PY, Migliorini D, Vonderheide RH, Domchek SM. Schiller JT, et al. Cancer Cell. 2022 Jun 13;40(6):559-564. doi: 10.1016/j.ccell.2022.05.015. Cancer Cell. 2022. PMID: 35700704 Free PMC article.
Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes …
Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of …
COVID-19 Vaccine Hesitancy Among Medicare Beneficiaries with and Without Cancer History: A US Population-based Study.
Poghosyan H, Ni Z, Vlahov D, Nelson L, Nam S. Poghosyan H, et al. J Community Health. 2022 Nov 25:1-10. doi: 10.1007/s10900-022-01174-5. Online ahead of print. J Community Health. 2022. PMID: 36427111 Free PMC article.
Understanding COVID-19 vaccine hesitancy among Medicare beneficiaries is critical for increasing COVID-19 vaccine uptake in the US. This study aimed to estimate and compare the vaccine hesitancy rate among community-dwelling Medicare beneficiari …
Understanding COVID-19 vaccine hesitancy among Medicare beneficiaries is critical for increasing COVID-19 vaccine
COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional survey.
Scanlon B, Wyld D, Firman P, Nakagaki M, Durham J, Kennedy G, Moran P, Smith M, Gavin N. Scanlon B, et al. Aust Health Rev. 2022 Dec 8. doi: 10.1071/AH22142. Online ahead of print. Aust Health Rev. 2022. PMID: 36476744
ObjectiveThis study aimed to investigate COVID-19 vaccine hesitancy, acceptance, and unmet informational needs in a cancer population during the first phase of the coronavirus disease 2019 (COVID-19) vaccination rollout in Australia.MethodsA cross-sect …
ObjectiveThis study aimed to investigate COVID-19 vaccine hesitancy, acceptance, and unmet informational needs in a cancer
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection.
Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, Ferrall L, Hung CF, Wu TC. Chi WY, et al. J Biomed Sci. 2022 Oct 15;29(1):82. doi: 10.1186/s12929-022-00853-8. J Biomed Sci. 2022. PMID: 36243868 Free PMC article. Review.
Coronavirus Disease 2019 (COVID-19) has been the most severe public health challenge in this century. ...To this end, we hope to provide essential knowledge for researchers who work on the improvement of future COVID-19 vaccines. In this review, we provided an up-to …
Coronavirus Disease 2019 (COVID-19) has been the most severe public health challenge in this century. ...To this end, we hope to prov …
Thrombosis, cancer, and COVID-19.
Brito-Dellan N, Tsoukalas N, Font C. Brito-Dellan N, et al. Support Care Cancer. 2022 Oct;30(10):8491-8500. doi: 10.1007/s00520-022-07098-z. Epub 2022 May 14. Support Care Cancer. 2022. PMID: 35567609 Free PMC article. Review.
Cancer patients are more vulnerable to COVID-19 infection and have a higher mortality rate. ...The mainstay of thrombosis treatment in patients with cancer and COVID-19 is anticoagulation therapy....
Cancer patients are more vulnerable to COVID-19 infection and have a higher mortality rate. ...The mainstay of thrombosis trea
mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients.
Azzolini E, Pozzi C, Germagnoli L, Oresta B, Carriglio N, Calleri M, Selmi C, De Santis M, Finazzi S, Carlo-Stella C, Bertuzzi A, Motta F, Ceribelli A, Mantovani A, Bonelli F, Rescigno M. Azzolini E, et al. Life Sci Alliance. 2022 Feb 15;5(6):e202201381. doi: 10.26508/lsa.202201381. Print 2022 Jun. Life Sci Alliance. 2022. PMID: 35169017 Free PMC article.
We tested the kinetic of development of serum antibodies to the SARS-CoV-2 Spike protein, their neutralizing capacity, the CD4 and CD8 IFN-gamma T-cell response in 328 subjects, including 131 immunocompromised individuals (cancer, rheumatologic, and hemodialysis patients), …
We tested the kinetic of development of serum antibodies to the SARS-CoV-2 Spike protein, their neutralizing capacity, the CD4 and CD8 IFN-g …
Attitudes toward a COVID-19 vaccine and vaccination status in cancer patients: a cross-sectional survey.
Heyne S, Esser P, Werner A, Lehmann-Laue A, Mehnert-Theuerkauf A. Heyne S, et al. J Cancer Res Clin Oncol. 2022 Jun;148(6):1363-1374. doi: 10.1007/s00432-022-03961-y. Epub 2022 Feb 26. J Cancer Res Clin Oncol. 2022. PMID: 35218401 Free PMC article.
The vaccination readiness among nonvaccinated cancer survivors was low to very low with "fear of side effects" the most mentioned (72.2%) reason against a COVID-19 vaccine. ...CONCLUSIONS: Majority of respondents are positive about COVID-19 vaccine
The vaccination readiness among nonvaccinated cancer survivors was low to very low with "fear of side effects" the most mentioned (72 …
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis.
Teh JSK, Coussement J, Neoh ZCF, Spelman T, Lazarakis S, Slavin MA, Teh BW. Teh JSK, et al. Blood Adv. 2022 Apr 12;6(7):2014-2034. doi: 10.1182/bloodadvances.2021006333. Blood Adv. 2022. PMID: 34852173 Free PMC article.
Primary outcome was the rate of seropositivity after 2 doses of COVID-19 vaccine with rates of seropositivity after 1 dose, rates of positive neutralizing antibodies, cellular responses, and adverse events as secondary outcomes. ...Active treatment, ongoing or recen …
Primary outcome was the rate of seropositivity after 2 doses of COVID-19 vaccine with rates of seropositivity after 1 dose, ra …
Heterologous prime-boost strategies for COVID-19 vaccines.
Sapkota B, Saud B, Shrestha R, Al-Fahad D, Sah R, Shrestha S, Rodriguez-Morales AJ. Sapkota B, et al. J Travel Med. 2022 May 31;29(3):taab191. doi: 10.1093/jtm/taab191. J Travel Med. 2022. PMID: 34918097 Free PMC article. Review.
BACKGROUND/OBJECTIVE: Heterologous prime-boost doses of COVID-19 vaccines ('mix-and-match' approach) are being studied to test for the effectiveness of Oxford (AZD1222), Pfizer (BNT162b2), Moderna (mRNA-1273) and Novavax (NVX-CoV2373) vaccines for COVID in 'Com-Cov2 …
BACKGROUND/OBJECTIVE: Heterologous prime-boost doses of COVID-19 vaccines ('mix-and-match' approach) are being studied to test for th …
Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs.
Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Seneff S, et al. Food Chem Toxicol. 2022 Jun;164:113008. doi: 10.1016/j.fct.2022.113008. Epub 2022 Apr 15. Food Chem Toxicol. 2022. PMID: 35436552 Free PMC article.
The mRNA SARS-CoV-2 vaccines were brought to market in response to the public health crises of Covid-19. The utilization of mRNA vaccines in the context of infectious disease has no precedent. The many alterations in the vaccine mRNA hide the mRNA from cellular defe …
The mRNA SARS-CoV-2 vaccines were brought to market in response to the public health crises of Covid-19. The utilization of mRNA vacc …
Evaluation of Safety and Side Effects COVID-19 Vaccine in Cancer Patients Being Treated.
Aznab M, Chalehchaleh M, Dokoshkani S, Rezaei M. Aznab M, et al. Asian Pac J Cancer Prev. 2022 Apr 1;23(4):1263-1270. doi: 10.31557/APJCP.2022.23.4.1263. Asian Pac J Cancer Prev. 2022. PMID: 35485684 Free PMC article.
According to the instructions of Iran's National Corona Response Committee in the Iranian Ministry of Health and Medical Education, patients undergoing treatments for their cancer are prioritized in Covid-19 vaccination. The present study was therefore conducted to …
According to the instructions of Iran's National Corona Response Committee in the Iranian Ministry of Health and Medical Education, patients …
Cancer Patients and the COVID-19 Vaccines: Considerations and Challenges.
Almasri M, Bshesh K, Khan W, Mushannen M, Salameh MA, Shafiq A, Vattoth AL, Elkassas N, Zakaria D. Almasri M, et al. Cancers (Basel). 2022 Nov 16;14(22):5630. doi: 10.3390/cancers14225630. Cancers (Basel). 2022. PMID: 36428722 Free PMC article. Review.
Few guidelines exist for COVID-19 vaccination amongst cancer patients, fostering uncertainty regarding the immunogenicity, safety, and effects of cancer therapies on vaccination, which this review aims to address. ...Additionally, radiation recall phenomenon …
Few guidelines exist for COVID-19 vaccination amongst cancer patients, fostering uncertainty regarding the immunogenicity, saf …
Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study.
Nakashima K, Ishida M, Matsui H, Yoshida C, Nagai T, Shiraga M, Nakaoka H, Otsuka Y, Nakagama Y, Kaku N, Nitahara Y, Kido Y, Hirota Y. Nakashima K, et al. Hum Vaccin Immunother. 2022 Nov 30;18(6):2140549. doi: 10.1080/21645515.2022.2140549. Epub 2022 Nov 11. Hum Vaccin Immunother. 2022. PMID: 36369871 Free PMC article.
This study assessed the immunogenicity and safety of the BNT162b2 mRNA vaccine in lung cancer patients receiving anticancer treatment. We enrolled lung cancer patients receiving anticancer treatment and non-cancer patients; all participants were fully …
This study assessed the immunogenicity and safety of the BNT162b2 mRNA vaccine in lung cancer patients receiving anticancer tr …
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans.
Leuva H, Zhou M, Brau N, Brown ST, Mundi P, Rosenberg TM, Luhrs C, Bates SE, Park YA, Fojo T. Leuva H, et al. Semin Oncol. 2022 Oct;49(5):363-370. doi: 10.1053/j.seminoncol.2022.07.005. Epub 2022 Aug 5. Semin Oncol. 2022. PMID: 36055952 Free PMC article.
Amongst risk factors proposed, a diagnosis of cancer has been worrisome. We report the impact of cancer and other risk factors in US Veterans receiving care at Veterans Administration (VA) Hospitals, their adjusted odds ratio (aOR) for infection and death, and repor …
Amongst risk factors proposed, a diagnosis of cancer has been worrisome. We report the impact of cancer and other risk factors …
Intranasal COVID-19 vaccines: From bench to bed.
Alu A, Chen L, Lei H, Wei Y, Tian X, Wei X. Alu A, et al. EBioMedicine. 2022 Feb;76:103841. doi: 10.1016/j.ebiom.2022.103841. Epub 2022 Jan 24. EBioMedicine. 2022. PMID: 35085851 Free PMC article. Review.
Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization. ...Despite the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, the next generation of COVID-19 vaccine is in demand and intranasal (IN) …
Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization. ...Despite the emerging severe acute respi …
The intention to get COVID-19 vaccine and vaccine uptake among cancer patients: An extension of the theory of planned behaviour (TPB).
Servidio R, Malvaso A, Vizza D, Valente M, Campagna MR, Iacono ML, Martin LR, Bruno F. Servidio R, et al. Support Care Cancer. 2022 Oct;30(10):7973-7982. doi: 10.1007/s00520-022-07238-5. Epub 2022 Jun 25. Support Care Cancer. 2022. PMID: 35752690 Free PMC article.
Therefore, the objective of the current study was to examine the predictors of cancer patients' intentions to receive COVID-19 vaccinations and vaccine uptake, using and integrating the theory of planned behaviour (TPB) and the health belief model (HBM). ...T …
Therefore, the objective of the current study was to examine the predictors of cancer patients' intentions to receive COVID-19 …
Drivers of COVID-19 Vaccine Intent Among Survivors of Adolescent and Young Adult Cancer: a Mixed Method Study.
Waters AR, Anderson JS, Mann K, Lopez PLV, Kepka D, Kirchhoff AC, Warner EL. Waters AR, et al. J Cancer Educ. 2022 Mar 28:1-9. doi: 10.1007/s13187-022-02155-x. Online ahead of print. J Cancer Educ. 2022. PMID: 35344162 Free PMC article.
Drivers of COVID-19 vaccine hesitancy and willingness are largely unexplored among AYA cancer survivors. ...CONCLUSIONS: Common drivers of COVID-19 vaccine hesitancy among survivors of AYA cancer include concern about vaccine side …
Drivers of COVID-19 vaccine hesitancy and willingness are largely unexplored among AYA cancer survivors. ...CONCLUSIONS …
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis.
Mai AS, Lee ARYB, Tay RYK, Shapiro L, Thakkar A, Halmos B, Grinshpun A, Herishanu Y, Benjamini O, Tadmor T, Shroff RT, LaFleur BJ, Bhattacharya D, Peng S, Tey J, Lee SC, Chai LYA, Soon YY, Sundar R, Lee MX. Mai AS, et al. Eur J Cancer. 2022 Sep;172:65-75. doi: 10.1016/j.ejca.2022.05.029. Epub 2022 Jun 3. Eur J Cancer. 2022. PMID: 35753213 Free PMC article. Review.
IMPORTANCE: Patients with cancer have an increased risk of severe disease and mortality from COVID-19, as the disease and antineoplastic therapy cause reduced vaccine immunogenicity. ...CONCLUSIONS: administration of a COVID-19 vaccine booster d …
IMPORTANCE: Patients with cancer have an increased risk of severe disease and mortality from COVID-19, as the disease and anti …
Menstrual Symptoms After COVID-19 Vaccine: A Cross-Sectional Investigation in the MENA Region.
Muhaidat N, Alshrouf MA, Azzam MI, Karam AM, Al-Nazer MW, Al-Ani A. Muhaidat N, et al. Int J Womens Health. 2022 Mar 28;14:395-404. doi: 10.2147/IJWH.S352167. eCollection 2022. Int J Womens Health. 2022. PMID: 35378876 Free PMC article.
The aim of this study is to investigate the prevalence and impact of menstrual abnormalities after the COVID-19 vaccine among females residing within the Middle East and North Africa (MENA). ...Participants who had confirmed previous COVID-19 infection had a …
The aim of this study is to investigate the prevalence and impact of menstrual abnormalities after the COVID-19 vaccine among …
The Relationship Between Covid-19 Risk Perception and Vaccine Hesitancy in Cancer Patients: The Moderating Role of Externalizing Traits.
Cheli S, Pino MS, Goldzweig G, Scoccianti S, Fabbroni V, Giordano C, Cavalletti V, Bassetti A, Fioretto L. Cheli S, et al. Clin Neuropsychiatry. 2022 Dec;19(6):355-364. doi: 10.36131/cnfioritieditore20220602. Clin Neuropsychiatry. 2022. PMID: 36627943 Free PMC article.
OBJECTIVE: This mixed-methods study aimed to explore the role of externalizing traits in moderating the relationship between COVID-19 risk perception and vaccine hesitancy in patients diagnosed with cancer. ...RESULTS: Phenomenological analysis suggested a pi …
OBJECTIVE: This mixed-methods study aimed to explore the role of externalizing traits in moderating the relationship between COVID-19 …
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Takai R, Nose T, Ohata S, Nagatani Y, Koyama T, Kitao A, Nishimura M, Imamura Y, Kiyota N, Harada K, Tanaka Y, Mori Y, Minami H. Funakoshi Y, et al. J Infect Chemother. 2022 Apr;28(4):516-520. doi: 10.1016/j.jiac.2021.12.021. Epub 2021 Dec 30. J Infect Chemother. 2022. PMID: 35090826 Free PMC article.
BACKGROUND: Although COVID-19 severity in cancer patients is high, the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing chemotherapy for solid cancers in Japan have not been reported. ...We evaluated serum IgG anti …
BACKGROUND: Although COVID-19 severity in cancer patients is high, the safety and immunogenicity of the BNT162b2 mRNA COVID
Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation.
Rolfo C, Meshulami N, Russo A, Krammer F, García-Sastre A, Mack PC, Gomez JE, Bhardwaj N, Benyounes A, Sirera R, Moore A, Rohs N, Henschke CI, Yankelevitz D, King J, Shyr Y, Bunn PA Jr, Minna JD, Hirsch FR. Rolfo C, et al. J Thorac Oncol. 2022 Feb;17(2):214-227. doi: 10.1016/j.jtho.2021.11.001. Epub 2021 Nov 10. J Thorac Oncol. 2022. PMID: 34774792 Free PMC article. Review.
In addition, beyond the direct impact of the pandemic on morbidity and mortality among patients with lung cancer, COVID-19, with its disruption of patient care, has also resulted in substantial impact on lung cancer screening and treatment/management.COVID
In addition, beyond the direct impact of the pandemic on morbidity and mortality among patients with lung cancer, COVID-19, wi …
Impact of corona-phobia on attitudes and acceptance towards COVID-19 vaccine among cancer patients: a single-center study.
Erdem D, Karaman I. Erdem D, et al. Future Oncol. 2022 Feb;18(4):457-469. doi: 10.2217/fon-2021-1015. Epub 2021 Dec 1. Future Oncol. 2022. PMID: 34851155 Free PMC article.
Aim: This study aimed to assess the impact of COVID-19 phobia and related factors on attitude towards COVID-19 vaccine in cancer patients. ...Minimizing negative attitudes towards vaccines will most likely be achieved by raising awareness in the can
Aim: This study aimed to assess the impact of COVID-19 phobia and related factors on attitude towards COVID-19 vaccine
COVID-19 vaccination in patients with cancer: Opportunities and challenges.
Al-Qaim ZH, Owadh HKH, Ali SA, Hussein AS, Ameen TR, Kolemen A, Washi GA, Jalil AT. Al-Qaim ZH, et al. Front Oncol. 2022 Nov 8;12:1029325. doi: 10.3389/fonc.2022.1029325. eCollection 2022. Front Oncol. 2022. PMID: 36425557 Free PMC article. Review.
Studies have confirmed the increased risk of severe Covid-19 disease and mortality in cancer patients. It is logical that cancer patients should be the first to receive the primary vaccination and the booster vaccine for Covid-19. Since studies …
Studies have confirmed the increased risk of severe Covid-19 disease and mortality in cancer patients. It is logical that c
Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients.
Ligumsky H, Safadi E, Etan T, Vaknin N, Waller M, Croll A, Nikolaevski-Berlin A, Greenberg I, Halperin T, Wasserman A, Galazan L, Arber N, Wolf I. Ligumsky H, et al. J Natl Cancer Inst. 2022 Feb 7;114(2):203-209. doi: 10.1093/jnci/djab174. J Natl Cancer Inst. 2022. PMID: 34453830 Free PMC article.
METHODS: We conducted a retrospective study of 326 patients with solid tumors treated with anticancer medications to determine the proportion of cancer patients with immunogenicity against SARS-CoV-2 following 2 doses of the BNT162b2 vaccine. ...Titers were also sta …
METHODS: We conducted a retrospective study of 326 patients with solid tumors treated with anticancer medications to determine the proportio …
Using Behavioral Science to Address COVID-19 Vaccine Hesitancy Among Cancer Survivors: Communication Strategies and Research Opportunities.
Vanderpool RC, Gaysynsky A, Chou WS, Tonorezos ES. Vanderpool RC, et al. J Behav Med. 2022 Mar 19:1-11. doi: 10.1007/s10865-022-00304-7. Online ahead of print. J Behav Med. 2022. PMID: 35305205 Free PMC article.
Due to cancer survivors' increased vulnerability to complications from COVID-19, addressing vaccine hesitancy and improving vaccine uptake among this population is a public health priority. However, several factors may complicate efforts to increase …
Due to cancer survivors' increased vulnerability to complications from COVID-19, addressing vaccine hesitancy and impro …
Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.
Corti C, Antonarelli G, Scotté F, Spano JP, Barrière J, Michot JM, André F, Curigliano G. Corti C, et al. Ann Oncol. 2022 Feb;33(2):158-168. doi: 10.1016/j.annonc.2021.10.014. Epub 2021 Oct 28. Ann Oncol. 2022. PMID: 34718117 Free PMC article. Review.
Since the history of cancer was linked to higher mortality rates due to COVID-19, the establishment of a safe and effective vaccine coverage is crucial in these patients. However, patients with cancer (PsC) were mostly excluded from vaccine cand …
Since the history of cancer was linked to higher mortality rates due to COVID-19, the establishment of a safe and effective …
Immune Response and Effects of COVID-19 Vaccination in Patients with Lung Cancer-COVID Lung Vaccine Study.
Hernandez A, Boigues M, Felip E, Cucurull M, Notario L, Pous A, Torres P, Benitez M, Rodriguez M, Quirant B, Romeo M, Fuster D, Moran T. Hernandez A, et al. Cancers (Basel). 2022 Dec 26;15(1):137. doi: 10.3390/cancers15010137. Cancers (Basel). 2022. PMID: 36612134 Free PMC article.
Detailed clinical data were also collected. In total, 126 patients with lung cancer participated and received at least one dose of the SARS-CoV-2 vaccine. ...In this lung cancer cohort, COVID-19 vaccines were safe and effective irrespective of the syst …
Detailed clinical data were also collected. In total, 126 patients with lung cancer participated and received at least one dose of th …
COVID-19 Vaccines and Immunosuppressed Patients With Cancer: Critical Considerations.
Cazeau N, Palazzo M, Savani M, Shroff RT. Cazeau N, et al. Clin J Oncol Nurs. 2022 Jul 25;26(4):367-373. doi: 10.1188/22.CJON.367-373. Clin J Oncol Nurs. 2022. PMID: 35939727 Free PMC article.
Emerging data characterize the impact of COVID-19 vaccines related to cancer malignancies and treatments. OBJECTIVES: &nbsp;This article provides a clinical foundation on the immune response to the COVID-19 vaccine associated with the impact of …
Emerging data characterize the impact of COVID-19 vaccines related to cancer malignancies and treatments. OBJECTIVES: &nbs …
Vaccine hesitancy and COVID-19 immunization among rural young adults.
Mann S, Christini K, Chai Y, Chang CP, Hashibe M, Kepka D. Mann S, et al. Prev Med Rep. 2022 Aug;28:101845. doi: 10.1016/j.pmedr.2022.101845. Epub 2022 Jun 2. Prev Med Rep. 2022. PMID: 35669235 Free PMC article.
Rural young adults may be more averse to receiving a COVID-19 immunization than urban young adults. We aimed to assess differences in COVID-19 vaccine hesitancy for rural, compared with urban, young adults and characterize modifiable factors. ...Rural partici …
Rural young adults may be more averse to receiving a COVID-19 immunization than urban young adults. We aimed to assess differences in …
Factors Associated with COVID‑19 Vaccine Uptake Among Adolescents and Young Adults Recently Diagnosed with Cancer.
Kwok G, Reese S, Dugad S, Donovan KA, Tsui J, Sahler OJZ, Levonyan-Radloff K, Barnett ME, Manne S, Ohman-Strickland P, Devine KA. Kwok G, et al. J Adolesc Young Adult Oncol. 2022 Nov 11. doi: 10.1089/jayao.2022.0113. Online ahead of print. J Adolesc Young Adult Oncol. 2022. PMID: 36367717
Adolescents and young adults (AYAs) recently diagnosed with cancer are medically vulnerable but little is known about vaccine uptake/intent in this group. AYAs reported on their COVID-19 vaccine uptake/intent. Logistic regression models examined factor …
Adolescents and young adults (AYAs) recently diagnosed with cancer are medically vulnerable but little is known about vaccine
Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic.
Bian DJH, Sabri S, Abdulkarim BS. Bian DJH, et al. Cancers (Basel). 2022 Jul 23;14(15):3598. doi: 10.3390/cancers14153598. Cancers (Basel). 2022. PMID: 35892857 Free PMC article. Review.
Cancer patients, specifically lung cancer patients, show heightened vulnerability to severe COVID-19 outcomes. The immunological and inflammatory pathophysiological similarities between lung cancer and COVID-19-related ARDS might explain the pre
Cancer patients, specifically lung cancer patients, show heightened vulnerability to severe COVID-19 outcomes. The immu
Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
Mei Q, Hu G, Yang Y, Liu B, Yin J, Li M, Huang Q, Tang X, Böhner A, Bryant A, Kurts C, Yuan X, Li J. Mei Q, et al. J Immunother Cancer. 2022 Mar;10(3):e004157. doi: 10.1136/jitc-2021-004157. J Immunother Cancer. 2022. PMID: 35264438 Free PMC article.
Anti-COVID-19 vaccination may have functional implications for immune checkpoint inhibitor treatment in patients with cancer. ...Thus, we conclude that patients with cancer need not suspend anti-PD-1 treatment during COVID-19 vaccination....
Anti-COVID-19 vaccination may have functional implications for immune checkpoint inhibitor treatment in patients with cancer. …
Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer.
Connors JM, Iba T. Connors JM, et al. Thromb Res. 2022 May;213 Suppl 1:S77-S83. doi: 10.1016/j.thromres.2022.02.009. Epub 2022 May 26. Thromb Res. 2022. PMID: 36210565 Free PMC article. Review.
Vaccines to combat SARS-CoV-2 infection and the COVID-19 pandemic were quickly developed due to significant and combined efforts by the scientific community, government agencies, and private sector pharmaceutical and biotechnology companies. Following vaccine develo …
Vaccines to combat SARS-CoV-2 infection and the COVID-19 pandemic were quickly developed due to significant and combined efforts by t …
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study.
De Placido P, Pietroluongo E, De Angelis C, Tafuro M, Barraco C, Giannatiempo R, Buonaiuto R, Schettini F, Iervolino A, Vozzella EA, Giuliano M, Bianco R, Arpino G. De Placido P, et al. Front Oncol. 2022 Aug 19;12:951026. doi: 10.3389/fonc.2022.951026. eCollection 2022. Front Oncol. 2022. PMID: 36059663 Free PMC article.
This study evaluates the efficacy and safety of the Pfizer/BioNTech BNT162b2 (BNT162b2) vaccine in patients with breast and gynecological cancer treated with active anticancer therapy versus a control cohort of healthy participants. ...RESULTS: Overall, 43/50 (86%) …
This study evaluates the efficacy and safety of the Pfizer/BioNTech BNT162b2 (BNT162b2) vaccine in patients with breast and gynecolog …
Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review.
Chua TH, Takano A. Chua TH, et al. J Clin Med. 2022 Oct 25;11(21):6290. doi: 10.3390/jcm11216290. J Clin Med. 2022. PMID: 36362518 Free PMC article. Review.
COVID-19 vaccine-associated lymphadenopathy (C19-VAL) is increasingly encountered with the widespread use of the vaccine in controlling the outbreak. We aim to characterize the pathological findings of COVID-19 and non-COVID-19 vaccine-as
COVID-19 vaccine-associated lymphadenopathy (C19-VAL) is increasingly encountered with the widespread use of the vaccine
COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery.
Bungaro M, Passiglia F, Scagliotti GV. Bungaro M, et al. Biomedicines. 2022 Mar 26;10(4):776. doi: 10.3390/biomedicines10040776. Biomedicines. 2022. PMID: 35453526 Free PMC article. Review.
Lung cancer patients have been associated with an increased risk of COVID-19 infection, pulmonary complications, and worse survival outcomes compared to the general population. The world's leading professional organizations provided new recommendations for the diagn …
Lung cancer patients have been associated with an increased risk of COVID-19 infection, pulmonary complications, and worse sur …
Prayer frequency and COVID-19 vaccine hesitancy among older adults in Europe.
Tolstrup Wester C, Lybecker Scheel-Hincke L, Bovil T, Andersen-Ranberg K, Juel Ahrenfeldt L, Christian Hvidt N. Tolstrup Wester C, et al. Vaccine. 2022 Oct 19;40(44):6383-6390. doi: 10.1016/j.vaccine.2022.09.044. Epub 2022 Sep 26. Vaccine. 2022. PMID: 36182618 Free PMC article.
AIM: Differences in levels of vaccine uptake have emerged across Europe, and this may partly be explained by religious beliefs. ...CONCLUSIONS: These findings provide support for an association between daily prayer frequency and COVID-19 vaccine hesitancy, wi …
AIM: Differences in levels of vaccine uptake have emerged across Europe, and this may partly be explained by religious beliefs. ...CO …
COVID-19 vaccination perception and uptake among cancer patients in Guangzhou, China.
Fu L, Wu S, Wang B, Zheng W, Sun Y, Tian T, Zhang X, Xu L, Sun Y, Zhan J, Peng Z, Chen Y, Zou H. Fu L, et al. Hum Vaccin Immunother. 2022 Nov 30;18(6):2102329. doi: 10.1080/21645515.2022.2102329. Epub 2022 Aug 17. Hum Vaccin Immunother. 2022. PMID: 35976684 Free PMC article.
Patients with cancer are considered at high risk of COVID-19 related complications with higher mortality rates than healthy individuals. ...COVID-19 vaccination uptake among cancer patients was insufficient. ...
Patients with cancer are considered at high risk of COVID-19 related complications with higher mortality rates than healthy in …
The Interplay of Lung Cancer, COVID-19, and Vaccines.
Trivanović D, Peršurić Ž, Agaj A, Jakopović M, Samaržija M, Bitar L, Pavelić K. Trivanović D, et al. Int J Mol Sci. 2022 Dec 1;23(23):15067. doi: 10.3390/ijms232315067. Int J Mol Sci. 2022. PMID: 36499394 Free PMC article. Review.
In addition, these patients were not included in the pivotal clinical trials for COVID-19 vaccines. Therefore, considerable uncertainty remains regarding the management of cancer patients during the COVID-19 pandemic and the safety of COVID-19 vaccinat …
In addition, these patients were not included in the pivotal clinical trials for COVID-19 vaccines. Therefore, considerable uncertain …
An update on the impact of SARS-CoV-2 pandemic public awareness on cancer patients' COVID-19 vaccine compliance: Outcomes and recommendations.
Souan L, Sughayer MA, Abu Alhowr M, Ammar K, Bader SA. Souan L, et al. Front Public Health. 2022 Jul 22;10:923815. doi: 10.3389/fpubh.2022.923815. eCollection 2022. Front Public Health. 2022. PMID: 35937267 Free PMC article.
As a result, the public's perceptions were influenced by what they knew, the many sources of COVID-19 information, and how they interpreted it. With cancer patients continuing to oppose COVID-19 vaccines, we sought to investigate the COVID-19 pandemic …
As a result, the public's perceptions were influenced by what they knew, the many sources of COVID-19 information, and how they inter …
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study.
Lee LYW, Ionescu MC, Starkey T, Little M, Tilby M, Tripathy AR, Mckenzie HS, Al-Hajji Y, Appanna N, Barnard M, Benny L, Burnett A, Cattell EL, Clark JJ, Khan S, Ghafoor Q, Panneerselvam H, Illsley G, Harper-Wynne C, Hattersley RJ, Lee AJ, Lomas O, Liu JK, McCauley A, Pang M, Pascoe JS, Platt JR, Patel G, Patel V, Potter VA, Randle A, Rigg AS, Robinson TM, Roques TW, Roux RL, Rozmanowski S, Taylor H, Tuthill MH, Watts I, Williams S, Beggs A, Iveson T, Lee SM, Middleton G, Middleton M, Protheroe A, Fittall MW, Fowler T, Johnson P; UK Coronavirus Cancer Programme. Lee LYW, et al. Eur J Cancer. 2022 Nov;175:1-10. doi: 10.1016/j.ejca.2022.06.038. Epub 2022 Jul 13. Eur J Cancer. 2022. PMID: 36084618 Free PMC article.
METHODS: This study is a population-scale real-world evaluation of the United Kingdom's third dose vaccine booster programme for cancer patients from 8th December 2020 to 7th December 2021. ...Lower vaccine effectiveness was associated with a cancer di …
METHODS: This study is a population-scale real-world evaluation of the United Kingdom's third dose vaccine booster programme for c
COVID-19 immunization in people with cancer-Is it safe and efficient? What do we know?
Lazăr DE, Munteanu A. Lazăr DE, et al. Tumori. 2022 Oct;108(5):420-430. doi: 10.1177/03008916221090544. Epub 2022 Apr 15. Tumori. 2022. PMID: 35426773 Review.
Prior to the COVID-19 pandemic, vaccination of people with cancer or a recent history of cancer was advisable under specific conditions, depending on the type of vaccine (inactivated or live attenuated virus or bacterium), type of cancer, and wh …
Prior to the COVID-19 pandemic, vaccination of people with cancer or a recent history of cancer was advisable under spe …
Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis.
Yang W, Zhang D, Li Z, Zhang K. Yang W, et al. Eur J Cancer. 2022 Sep;172:41-50. doi: 10.1016/j.ejca.2022.05.031. Epub 2022 Jun 2. Eur J Cancer. 2022. PMID: 35752155 Free PMC article.
BACKGROUNDS: Patients with cancer presented a lower probability to obtain seroconversion after a complete course of COVID-19 vaccination. ...RESULTS: Twenty cohort studies met the inclusion criteria for this study, with 5,499 patients with cancer. We found th …
BACKGROUNDS: Patients with cancer presented a lower probability to obtain seroconversion after a complete course of COVID-19 v …
COVID-19 vaccine (mRNA BNT162b2) and COVID-19 infection-induced thrombotic thrombocytopenic purpura in adolescents.
Vorster L, Kirk SE, Muscal E, Despotovic JM, Cohen CT, Sartain SE. Vorster L, et al. Pediatr Blood Cancer. 2022 Jun;69(6):e29681. doi: 10.1002/pbc.29681. Epub 2022 Apr 4. Pediatr Blood Cancer. 2022. PMID: 35373880 Free PMC article.
The mRNA COVID-19 vaccine and COVID-19 infection caused by the SARS-CoV-2 virus may be immunologic triggers for the development of thrombotic thrombocytopenic purpura (TTP). ...We describe three adolescents presenting with TTP (both de novo and relapsed disea …
The mRNA COVID-19 vaccine and COVID-19 infection caused by the SARS-CoV-2 virus may be immunologic triggers for the dev …
COVID-19 Vaccine-Related Adverse Events in Solid Cancer Patients Treated with Immunotherapy.
Bouleftour W, Bonjean P, Grangeon K, Magné N. Bouleftour W, et al. Cancer Invest. 2022 Oct;40(9):760-766. doi: 10.1080/07357907.2022.2121966. Epub 2022 Sep 14. Cancer Invest. 2022. PMID: 36062881
Little data are available regarding the effects of COVID-19 vaccine in cancer patients undergoing immunotherapy. Thereby, COVID-19 vaccine-related adverse events were monitored through a short questionnaire in solid cancer patients receiv …
Little data are available regarding the effects of COVID-19 vaccine in cancer patients undergoing immunotherapy. Thereb …
COVID-19 Booster Vaccine Equity for Patients With Cancer.
Prasad RN, Patel M, Palmer JD. Prasad RN, et al. Adv Radiat Oncol. 2022 Sep-Oct;7(5):100939. doi: 10.1016/j.adro.2022.100939. Epub 2022 Mar 9. Adv Radiat Oncol. 2022. PMID: 35280348 Free PMC article.
COVID-19 has caused greater than 300 million documented infections worldwide including over 5 million confirmed deaths. Patients with cancer are particularly vulnerable due to a combination of disease and therapy-related effects. ...
COVID-19 has caused greater than 300 million documented infections worldwide including over 5 million confirmed deaths. Patients with
Between Healthcare Practitioners and Clergy: Evangelicals and COVID-19 Vaccine Hesitancy.
Guidry JPD, Miller CA, Perrin PB, Laestadius LI, Zurlo G, Savage MW, Stevens M, Fuemmeler BF, Burton CW, Gültzow T, Carlyle KE. Guidry JPD, et al. Int J Environ Res Public Health. 2022 Sep 5;19(17):11120. doi: 10.3390/ijerph191711120. Int J Environ Res Public Health. 2022. PMID: 36078836 Free PMC article.
Evangelical Christians are among the most hesitant to get the COVID-19 vaccine. This study examined the extent to which COVID-19 vaccination uptake among Evangelicals is explained by demographic characteristics, Health Belief Model constructs, and faith-based …
Evangelical Christians are among the most hesitant to get the COVID-19 vaccine. This study examined the extent to which COV
Factors affecting COVID-19 vaccine hesitancy in parents of children with cancer.
Skeens MA, Hill K, Olsavsky A, Buff K, Stevens J, Akard TF, Shah N, Gerhardt CA. Skeens MA, et al. Pediatr Blood Cancer. 2022 Jun;69(6):e29707. doi: 10.1002/pbc.29707. Epub 2022 Apr 5. Pediatr Blood Cancer. 2022. PMID: 35384278 Free PMC article.
AIM: Little research exists on coronavirus (COVID-19) vaccine hesitancy among caregivers of children with cancer. We aimed to (a) describe vaccine hesitancy in parents of children with cancer for both their child and self, and (b) examine the me …
AIM: Little research exists on coronavirus (COVID-19) vaccine hesitancy among caregivers of children with cancer. We ai …
Seroprevalence of IgM and IgG Against SARS-CoV-2 after Two Doses of Pfizer-BioNTech COVID-19 Vaccine in Women with Breast Cancer.
Almehmadi M, Salih MM, Shafie A, Alsharif A, Alsiwiehr N, El-Askary A, Alzahrani K, Al-Hazmi A, Aljuaid A, Abdulazziz O, Almalki AA, Allahyani M, Eed E, Alharbi AM, Halawi M, Allam HH, Abutawil H, Alosimi E, Gharib AF. Almehmadi M, et al. Clin Lab. 2022 Nov 1;68(11). doi: 10.7754/Clin.Lab.2022.220316. Clin Lab. 2022. PMID: 36378000
METHODS: Overall, 103 breast cancer patients were included. Individuals who had had two doses of Pfizer-BioNTech vaccine, patients who were earlier diagnosed with COVID-19 infection, had not finalized immunization plan, or who received the second dose recentl …
METHODS: Overall, 103 breast cancer patients were included. Individuals who had had two doses of Pfizer-BioNTech vaccine, pati …
COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies.
Goldman JD, Gonzalez MA, Rüthrich MM, Sharon E, von Lilienfeld-Toal M. Goldman JD, et al. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. doi: 10.1200/EDBK_359656. Am Soc Clin Oncol Educ Book. 2022. PMID: 35658503 Free article.
Patients with cancer generally have a higher risk of adverse outcomes from COVID-19, with higher age, male sex, poor performance status, cancer type, and uncontrolled malignant disease as the main risk factors. However, the influence of specific cancer
Patients with cancer generally have a higher risk of adverse outcomes from COVID-19, with higher age, male sex, poor performan …
Dendritic cell vaccine as a potential strategy to end the COVID-19 pandemic. Why should it be Ex Vivo?
Jonny J, Putranto TA, Sitepu EC, Irfon R. Jonny J, et al. Expert Rev Vaccines. 2022 Aug;21(8):1111-1120. doi: 10.1080/14760584.2022.2080658. Epub 2022 May 26. Expert Rev Vaccines. 2022. PMID: 35593184 Review.
However, the DCs-based vaccine with ex vivo loading has not yet been explored for COVID-19. ...EXPERT OPINION: We make the case that an ex vivo loaded DC-based vaccination is appropriate for COVID-19 prevention....
However, the DCs-based vaccine with ex vivo loading has not yet been explored for COVID-19. ...EXPERT OPINION: We make the cas …
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response.
Reimann P, Ulmer H, Mutschlechner B, Benda M, Severgnini L, Volgger A, Lang T, Atzl M, Huynh M, Gasser K, Grabher C, Mink S, Fraunberger P, Petrausch U, Hartmann B, Winder T. Reimann P, et al. Br J Haematol. 2022 Feb;196(3):577-584. doi: 10.1111/bjh.17982. Epub 2021 Dec 6. Br J Haematol. 2022. PMID: 34872162 Clinical Trial.
Patients with haemato-oncological malignancies are one of the high-risk groups for a severe course in case of COVID-19 infections. Furthermore, vaccination results in significantly lower response rates in haematological malignancies and lower antibody levels in patients wi …
Patients with haemato-oncological malignancies are one of the high-risk groups for a severe course in case of COVID-19 infections. Fu …
SARS-CoV-2-related and Covid-19 vaccine-induced thromboembolic events: A comparative review.
Afshar ZM, Barary M, Babazadeh A, Hosseinzadeh R, Alijanpour A, Miri SR, Sio TT, Sullman MJM, Carson-Chahhoud K, Langer F, Ebrahimpour S. Afshar ZM, et al. Rev Med Virol. 2022 Jul;32(4):e2327. doi: 10.1002/rmv.2327. Epub 2022 Feb 3. Rev Med Virol. 2022. PMID: 35112763 Review.
Nevertheless, the initiation of vaccination programs brought another rare yet highly fatal thrombotic event, vaccine-induced immune thrombotic thrombocytopaenia, which has caused extensive debate regarding the safety of vaccines. ...
Nevertheless, the initiation of vaccination programs brought another rare yet highly fatal thrombotic event, vaccine-induced immune t …
Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity.
Abdollahi A, Afsharyzad Y, Vaezi A, Meysamie A. Abdollahi A, et al. Vaccines (Basel). 2022 Oct 13;10(10):1708. doi: 10.3390/vaccines10101708. Vaccines (Basel). 2022. PMID: 36298573 Free PMC article.
METHODS: This cross-sectional study was conducted in a referral laboratory in Tehran, Iran. The level of COVID-19 antibodies was measured and compared between individuals regarding the number of COVID-19 vaccine shots. ...CONCLUSION: The results of our study …
METHODS: This cross-sectional study was conducted in a referral laboratory in Tehran, Iran. The level of COVID-19 antibodies was meas …
A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines.
Elberry MH, Abdelgawad HAH, Hamdallah A, Abdella WS, Ahmed AS, Ghaith HS, Negida A. Elberry MH, et al. J Thromb Thrombolysis. 2022 May;53(4):798-823. doi: 10.1007/s11239-021-02626-w. Epub 2022 Feb 14. J Thromb Thrombolysis. 2022. PMID: 35157188 Free PMC article. Review.
Reports of thrombotic response after receiving COVID-19 Adenoviral-Vector Based Vaccines raise concerns about vaccine-induced thrombotic thrombocytopenia (VITT); therefore, we conduct this systematic review to report susceptible demographics outcomes, commonalities, …
Reports of thrombotic response after receiving COVID-19 Adenoviral-Vector Based Vaccines raise concerns about vaccine-induced …
Third dose of SARS-CoV-2 vaccine: A systematic review of 30 published studies.
Petrelli F, Luciani A, Borgonovo K, Ghilardi M, Parati MC, Petrò D, Lonati V, Pesenti A, Cabiddu M. Petrelli F, et al. J Med Virol. 2022 Jun;94(6):2837-2844. doi: 10.1002/jmv.27644. Epub 2022 Feb 12. J Med Virol. 2022. PMID: 35118680 Free PMC article.
We analyzed published studies on the efficacy and safety of the third dose of the COVID-19 vaccine in various general population settings. We conducted systematic searches of PubMed and EMBASE for series published in the English language through November 15, 2021, u …
We analyzed published studies on the efficacy and safety of the third dose of the COVID-19 vaccine in various general populati …
COVID-19 vaccine effectiveness in patients with hematologic malignancy.
Shah DP, Shah PK, Thompson MA. Shah DP, et al. Transpl Infect Dis. 2022 Dec;24(6):e13850. doi: 10.1111/tid.13850. Epub 2022 Aug 16. Transpl Infect Dis. 2022. PMID: 35584967 Free PMC article.
COVID-19 vaccine response HM<solid. Breakthrough infections HM>solid. Vaccine effectiveness Population studies urgently needed. Early #COVID19CP could be lifesaving in immunocompromised HM pts. ...
COVID-19 vaccine response HM<solid. Breakthrough infections HM>solid. Vaccine effectiveness Population studies ur
Cancer patients and COVID-19 vaccination, from safety to protocol adherence: A real-life setting report.
Lamtai H, Boutayeb S, Mrabti H, El Ghissassi I, Errihani H. Lamtai H, et al. Front Oncol. 2022 Oct 3;12:1014786. doi: 10.3389/fonc.2022.1014786. eCollection 2022. Front Oncol. 2022. PMID: 36263207 Free PMC article.
BACKGROUND: The SARS-CoV-2 pandemic has slowed down cancer prevention and treatment strategies; consequently, cancer patients are prioritized to get the COVID-19 vaccines. ...Due to the fear of interactions with the therapy, we noticed a significant trend to …
BACKGROUND: The SARS-CoV-2 pandemic has slowed down cancer prevention and treatment strategies; consequently, cancer patients …
Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer.
Couderc AL, Ninove L, Nouguerède E, Rey D, Rebroin M, Daumas A, Tomasini P, Greillier L, Salas S, Duffaud F, Dahan L, Duluc M, Garcia ME, Pluvy J, Chaléat S, Farnault L, Venton G, Fourié T, Nurtop E, de Lamballerie X, Villani P, Charrel R, Correard F. Couderc AL, et al. J Geriatr Oncol. 2022 Jul;13(6):850-855. doi: 10.1016/j.jgo.2022.05.002. Epub 2022 May 16. J Geriatr Oncol. 2022. PMID: 35589542 Free PMC article.
Our study aimed to determine the level of acceptance of vaccination in a population of older patients with cancer. METHODS: From January 2021, we offered vaccination with the BNT162b2 COVID-19 vaccine to all patients 70 years and older referred to our geriatr …
Our study aimed to determine the level of acceptance of vaccination in a population of older patients with cancer. METHODS: From Janu …
Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis.
Sakuraba A, Luna A, Micic D. Sakuraba A, et al. J Hematol Oncol. 2022 Feb 5;15(1):15. doi: 10.1186/s13045-022-01233-3. J Hematol Oncol. 2022. PMID: 35123511 Free PMC article.
PURPOSE: Patients with cancer have an increased risk of coronavirus disease 2019 (COVID-19) and an attenuated responses to various vaccines. This meta-analysis aims to assess the serologic response to COVID-19 vaccination in patients with cancer. METHO …
PURPOSE: Patients with cancer have an increased risk of coronavirus disease 2019 (COVID-19) and an attenuated responses to var …
Time for Resolution of COVID-19 Vaccine-Related Axillary Lymphadenopathy and Associated Factors.
Lane EG, Eisen CS, Drotman MB, Dodelzon K, Mema E, Thomas C, Prince MR. Lane EG, et al. AJR Am J Roentgenol. 2022 Oct;219(4):559-568. doi: 10.2214/AJR.22.27687. Epub 2022 May 18. AJR Am J Roentgenol. 2022. PMID: 35583425
Axillary lymphadenopathy detected with breast ultrasound after COVID-19 mRNA vaccination lasts longer than reported in initial vaccine clinical trials. ...The prolonged time to resolution supports not delaying screening mammography because of recent COVID-19 …
Axillary lymphadenopathy detected with breast ultrasound after COVID-19 mRNA vaccination lasts longer than reported in initial vac
Understanding COVID Vaccination and Its Implication in Cancer Patients' Imaging of Lymph Nodes by PET-CT.
Gales LN, Brotea-Mosoiu S, Trifanescu OG, Lazar AM, Gherghe M. Gales LN, et al. Diagnostics (Basel). 2022 Sep 6;12(9):2163. doi: 10.3390/diagnostics12092163. Diagnostics (Basel). 2022. PMID: 36140564 Free PMC article.
(1) Background: The appearance of enlarged lymph nodes on imaging adds another layer of complexity to the differential diagnosis of disease progression versus immune response to COVID-19 vaccines. Our aim was to find an optimal timing between the vaccination and the PET-CT …
(1) Background: The appearance of enlarged lymph nodes on imaging adds another layer of complexity to the differential diagnosis of disease …
An Impact of COVID-19 on Cancer Care: An Update.
Chavda VP, Ping FF, Chen ZS. Chavda VP, et al. Vaccines (Basel). 2022 Dec 4;10(12):2072. doi: 10.3390/vaccines10122072. Vaccines (Basel). 2022. PMID: 36560482 Free PMC article. Review.
Clinical trials at the initial stage were performed on healthy or COVID-19 infected patients. This produces a greater level of hesitancy in cancer patients. This review article provide an update regarding the vaccination and treatment for COVID-19 in patients …
Clinical trials at the initial stage were performed on healthy or COVID-19 infected patients. This produces a greater level of hesita …
COVID-19 vaccine behaviors and intentions among a national sample of United States adults ages 18-45.
Brownstein NC, Reddy H, Whiting J, Kasting ML, Head KJ, Vadaparampil ST, Giuliano AR, Gwede CK, Meade CD, Christy SM. Brownstein NC, et al. Prev Med. 2022 Jul;160:107038. doi: 10.1016/j.ypmed.2022.107038. Epub 2022 Apr 7. Prev Med. 2022. PMID: 35398369 Free PMC article.
RESULTS: Among participants in the final analytic sample (n = 2722), 18% reported having received at least one dose of a COVID-19 vaccine. Approximately 31% of unvaccinated participants reported strong intentions to receive a COVID-19 vaccine in the ne …
RESULTS: Among participants in the final analytic sample (n = 2722), 18% reported having received at least one dose of a COVID-19 …
Covid-19 vaccine hesitancy and resistance amongst parents of children under 18 years of age in Ireland.
Ceannt R, Vallieres F, Burns H, Murphy J, Hyland P. Ceannt R, et al. Vaccine. 2022 Oct 12;40(43):6196-6200. doi: 10.1016/j.vaccine.2022.08.073. Epub 2022 Sep 7. Vaccine. 2022. PMID: 36127211 Free PMC article.
Compared to vaccine-accepting parents, hesitant parents were more likely to be younger, less educated, poorer, to not know somebody who was sick from COVID-19, to believe the COVID-19 vaccines were unsafe, and to hold negative beliefs about scientists and hea …
Compared to vaccine-accepting parents, hesitant parents were more likely to be younger, less educated, poorer, to not know somebody w …
COVID-19 vaccine literacy and vaccine hesitancy among pregnant women and mothers of young children in Japan.
Takahashi Y, Ishitsuka K, Sampei M, Okawa S, Hosokawa Y, Ishiguro A, Tabuchi T, Morisaki N. Takahashi Y, et al. Vaccine. 2022 Nov 8;40(47):6849-6856. doi: 10.1016/j.vaccine.2022.09.094. Epub 2022 Oct 17. Vaccine. 2022. PMID: 36266127 Free PMC article.
BACKGROUND: Delays in the spread of vaccination have been recognized as an urgent public health issue in the context of the COVID-19 pandemic. Vaccine literacy (VL) is a critical determinant of vaccine uptake; however, little is known about VL among pregnant …
BACKGROUND: Delays in the spread of vaccination have been recognized as an urgent public health issue in the context of the COVID-19 …
COVID-19 Vaccination in Patients with Cancer.
Suzuki H, Akiyama T, Ueda N, Matsumura S, Mori M, Namiki M, Yamada N, Tsutsumi C, Tozaki S, Iwamoto H, Torii S, Okubo Y, Ishiguro K. Suzuki H, et al. Cancers (Basel). 2022 May 23;14(10):2556. doi: 10.3390/cancers14102556. Cancers (Basel). 2022. PMID: 35626162 Free PMC article.
Patients with cancer are concerned about the effects of the COVID-19 vaccination. We conducted an online survey on the COVID-19 vaccination status and side effects among patients with cancer in Japan between 8 and 14 August 2021. ...
Patients with cancer are concerned about the effects of the COVID-19 vaccination. We conducted an online survey on the COVI
mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.
Deng Z, Tian Y, Song J, An G, Yang P. Deng Z, et al. Front Immunol. 2022 Jun 2;13:887125. doi: 10.3389/fimmu.2022.887125. eCollection 2022. Front Immunol. 2022. PMID: 35720301 Free PMC article. Review.
mRNA therapy is a novel anticancer strategy based on in vitro transcription (IVT), which has potential for the treatment of malignant tumors. The outbreak of the COVID-19 pandemic in the early 21st century has promoted the application of mRNA technologies in SARS-CoV-2 vac …
mRNA therapy is a novel anticancer strategy based on in vitro transcription (IVT), which has potential for the treatment of malignant tumors …
mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics.
Chavda VP, Soni S, Vora LK, Soni S, Khadela A, Ajabiya J. Chavda VP, et al. Vaccines (Basel). 2022 Dec 15;10(12):2150. doi: 10.3390/vaccines10122150. Vaccines (Basel). 2022. PMID: 36560560 Free PMC article. Review.
An unheard mobilization of resources to find SARS-CoV-2 vaccines and therapies has been sparked by the COVID-19 pandemic. Two years ago, COVID-19's launch propelled mRNA-based technologies into the public eye. ...In this review, we explore the potential of mRNA as a …
An unheard mobilization of resources to find SARS-CoV-2 vaccines and therapies has been sparked by the COVID-19 pandemic. Two years a …
Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol.
Munoz FM, Beigi RH, Posavad CM, Richardson BA, Chu HY, Bok K, Campbell J, Cardemil C, DeFranco E, Frenck RW, Makhene M, Piper JM, Sheffield J, Miller A, Neuzil KM. Munoz FM, et al. BMC Pregnancy Childbirth. 2022 May 12;22(1):402. doi: 10.1186/s12884-022-04500-w. BMC Pregnancy Childbirth. 2022. PMID: 35550037 Free PMC article.
BACKGROUND: Pregnant women were excluded from investigational trials of COVID-19 vaccines. Limited data are available to inform pregnant and postpartum women on their decisions to receive a COVID-19 vaccine. ...Approximately 200 pregnant women and 65 postpart …
BACKGROUND: Pregnant women were excluded from investigational trials of COVID-19 vaccines. Limited data are available to inform pregn …
COVID-19 Vaccine Hesitancy among Arab Americans.
Kheil MH, Jain D, Jomaa J, Askar B, Alcodray Y, Wahbi S, Brikho S, Kadouh A, Harajli D, Jawad ZN, Fehmi Z, Elhage M, Tawil T, Fehmi O, Alzouhayli SJ, Ujayli D, Suleiman N, Kazziha O, Saleh R, Abada E, Shallal A, Kim S, Kumar VA, Zervos M, Cote ML, Ali-Fehmi R. Kheil MH, et al. Vaccines (Basel). 2022 Apr 14;10(4):610. doi: 10.3390/vaccines10040610. Vaccines (Basel). 2022. PMID: 35455359 Free PMC article.
A total of 92% of respondents reported having received at least one dose of a COVID-19 vaccine. A total of 73% reported willingness to receive a booster, and 72% plan to give their children the vaccine. ...They were less likely to be vaccine-hesitant i …
A total of 92% of respondents reported having received at least one dose of a COVID-19 vaccine. A total of 73% reported willin …
COVID-19 vaccination in cancer patients: a narrative review.
Seneviratne SL, Yasawardene P, Wijerathne W, Somawardana B. Seneviratne SL, et al. J Int Med Res. 2022 Mar;50(3):3000605221086155. doi: 10.1177/03000605221086155. J Int Med Res. 2022. PMID: 35313761 Free PMC article. Review.
Consideration should be given to offering patients with cancer second doses of COVID vaccine at shorter intervals than in healthy individuals. Patients with cancer warrant a third vaccine dose and must be prioritized in vaccination schedules. .. …
Consideration should be given to offering patients with cancer second doses of COVID vaccine at shorter intervals than …
Innovative vaccine approaches-a Keystone Symposia report.
Cable J, Rappuoli R, Klemm EJ, Kang G, Mutreja A, Wright GJ, Pizza M, Castro SA, Hoffmann JP, Alter G, Carfi A, Pollard AJ, Krammer F, Gupta RK, Wagner CE, Machado V, Modjarrad K, Corey L, B Gilbert P, Dougan G, Lurie N, Bjorkman PJ, Chiu C, Nemes E, Gordon SB, Steer AC, Rudel T, Blish CA, Sandberg JT, Brennan K, Klugman KP, Stuart LM, Madhi SA, Karp CL. Cable J, et al. Ann N Y Acad Sci. 2022 May;1511(1):59-86. doi: 10.1111/nyas.14739. Epub 2022 Jan 14. Ann N Y Acad Sci. 2022. PMID: 35029310
The rapid development of COVID-19 vaccines was the result of decades of research to establish flexible vaccine platforms and understand pathogens with pandemic potential, as well as several novel changes to the vaccine discovery and development processes that …
The rapid development of COVID-19 vaccines was the result of decades of research to establish flexible vaccine platforms and u …
COVID-19 Vaccine Effectiveness in Oncology Patients.
LA Costa R. LA Costa R. J Adv Pract Oncol. 2022 May;13(4):441-447. doi: 10.6004/jadpro.2022.13.4.6. Epub 2022 Jun 21. J Adv Pract Oncol. 2022. PMID: 35755900 Free PMC article.
Oncology patients are at greater risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) infection than the general population. Patients with malignancies were prioritized in vaccine distribution to confer protection to a vulnerable population. Howe …
Oncology patients are at greater risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) infection than the general …
COVID-19 Vaccine-Associated Lymphadenopathy in Breast Imaging Recipients: A Review of Literature.
Aleman RT, Rauch J, Desai J, Chaiban JT. Aleman RT, et al. Cureus. 2022 Jul 14;14(7):e26845. doi: 10.7759/cureus.26845. eCollection 2022 Jul. Cureus. 2022. PMID: 35974844 Free PMC article. Review.
In patients undergoing routine screening and surveillance for breast cancer, interpreting lymphadenopathy (LAP) is challenging in the setting of a recent COVID-19 vaccination. ...In this comprehensive review, we summarize the existing literature on COVID-19 …
In patients undergoing routine screening and surveillance for breast cancer, interpreting lymphadenopathy (LAP) is challenging in the …
Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.
Jafari A, Danesh Pouya F, Niknam Z, Abdollahpour-Alitappeh M, Rezaei-Tavirani M, Rasmi Y. Jafari A, et al. Mol Biol Rep. 2022 Jun;49(6):4943-4957. doi: 10.1007/s11033-022-07132-7. Epub 2022 Mar 2. Mol Biol Rep. 2022. PMID: 35235159 Free PMC article. Review.
The world is grappling with an unprecedented public health crisis COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2. Due to the high transmission/mortality rates and socioeconomic impacts of the COVID-19, its control is crucial. ...Many companies around t …
The world is grappling with an unprecedented public health crisis COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2. Due t …
Perception and safety analysis of COVID-19 vaccination in cancer patients: A multicenter, real-world study.
Lee K, Park IH, Oh SC, Seo JH, Jeon MJ, Yu ES, Kim DS, Choi CW, Lim AR, Hyun MH, Kim JW, Kim JH, Choi YJ, Lee S, Park KH, Kim YH, Choi JY, Kim JS, Lee SR, Sung HJ, Kang EJ. Lee K, et al. Cancer Med. 2022 Nov 13:10.1002/cam4.5400. doi: 10.1002/cam4.5400. Online ahead of print. Cancer Med. 2022. PMID: 36373165 Free PMC article.
Vaccine hesitancy related to safety concerns is observed among cancer patients. We report the perception of COVID-19 vaccines and their safety profile after vaccination among cancer patients. ...
Vaccine hesitancy related to safety concerns is observed among cancer patients. We report the perception of COVID-19 va
Coincidence of Sarcoidosis and a COVID-19 vaccine-associated hypermetabolic lymphadenopathy in a patient with a history of invasive breast cancer: A case report.
Kawabata A, Nakamura T, Suzuki H, Yoshida M, Otsuki Y, Mori N. Kawabata A, et al. Int J Surg Case Rep. 2022 May;94:107098. doi: 10.1016/j.ijscr.2022.107098. Epub 2022 Apr 19. Int J Surg Case Rep. 2022. PMID: 35464072 Free PMC article.
INTRODUCTION AND IMPORTANCE: Vaccine-associated hypermetabolic lymphadenopathy (VAHL) after a COVID 19 vaccination is a common adverse event and also a diagnostic challenge especially in patients with a history of a malignancy. ...CLINICAL DISCUSSION: The coincident …
INTRODUCTION AND IMPORTANCE: Vaccine-associated hypermetabolic lymphadenopathy (VAHL) after a COVID 19 vaccination is a common …
Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies.
Thompson MA, Hallmeyer S, Fitzpatrick VE, Liao Y, Mullane MP, Medlin SC, Copeland K, Weese JL. Thompson MA, et al. J Patient Cent Res Rev. 2022 Jul 18;9(3):149-157. doi: 10.17294/2330-0698.1952. eCollection 2022 Summer. J Patient Cent Res Rev. 2022. PMID: 35935520 Free PMC article.
PURPOSE: This study sought to describe the changes in immune response to a third dose of either Pfizer's or Moderna's COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics. ...Results showed a statistically si …
PURPOSE: This study sought to describe the changes in immune response to a third dose of either Pfizer's or Moderna's COVID-19 mRNA …
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.
Lee LYW, Starkey T, Ionescu MC, Little M, Tilby M, Tripathy AR, Mckenzie HS, Al-Hajji Y, Barnard M, Benny L, Burnett A, Cattell EL, Charman J, Clark JJ, Khan S, Ghafoor Q, Illsley G, Harper-Wynne C, Hattersley RJ, Lee AJX, Leonard PC, Liu JKH; NCRI Consumer Forum; Pang M, Pascoe JS, Platt JR, Potter VA, Randle A, Rigg AS, Robinson TM, Roques TW, Roux RL, Rozmanowski S, Tuthill MH, Watts I, Williams S, Iveson T, Lee SM, Middleton G, Middleton M, Protheroe A, Fittall MW, Fowler T, Johnson P. Lee LYW, et al. Lancet Oncol. 2022 Jun;23(6):748-757. doi: 10.1016/S1470-2045(22)00202-9. Epub 2022 May 23. Lancet Oncol. 2022. PMID: 35617989 Free PMC article.
However, vaccine effectiveness is lower in patients with cancer than in the general population. COVID-19 vaccination for patients with cancer should be used in conjunction with non-pharmacological strategies and community-based antiviral treatment prog …
However, vaccine effectiveness is lower in patients with cancer than in the general population. COVID-19 vaccination fo …
Value-based pricing of a COVID-19 vaccine.
Gandjour A. Gandjour A. Q Rev Econ Finance. 2022 May;84:1-8. doi: 10.1016/j.qref.2021.12.006. Epub 2021 Dec 24. Q Rev Econ Finance. 2022. PMID: 34975265 Free PMC article.
The value of an additional life year was borrowed from new, innovative oncological drugs, as cancer reflects a condition with a similar morbidity and mortality burden in the general population in the short term as COVID-19. ...CONCLUSION: This study yields a value-b …
The value of an additional life year was borrowed from new, innovative oncological drugs, as cancer reflects a condition with a simil …
COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19).
Seegers V, Rousseau G, Zhou K, Blanc-Lapierre A, Bigot F, Mahammedi H, Lambert A, Moreau-Bachelard C, Campone M, Conroy T, Penault-Llorca F, Boisdron-Celle M, Bellanger M, Raoul JL. Seegers V, et al. Cancers (Basel). 2022 Nov 11;14(22):5547. doi: 10.3390/cancers14225547. Cancers (Basel). 2022. PMID: 36428640 Free PMC article.
In this prospective, real-life cohort study, we followed 523 cancer patients (CP) and 579 healthcare workers (HCW) from two cancer centers to evaluate the biological and clinical results of the COVID-19 vaccination campaign. Seventy percent of the CP and 90% …
In this prospective, real-life cohort study, we followed 523 cancer patients (CP) and 579 healthcare workers (HCW) from two cancer
Human papillomavirus vaccine uptake among teens before and during the COVID-19 pandemic in the United States.
Abouelella DK, Canick JE, Barnes JM, Rohde RL, Watts TL, Adjei Boakye E, Osazuwa-Peters N. Abouelella DK, et al. Hum Vaccin Immunother. 2022 Dec 30;18(7):2148825. doi: 10.1080/21645515.2022.2148825. Epub 2022 Dec 9. Hum Vaccin Immunother. 2022. PMID: 36484115 Free PMC article.
It is unclear how the COVID-19 pandemic impacted human papillomavirus (HPV) vaccine uptake and which sociodemographic groups may have been most impacted. ...During the COVID-19 pandemic in 2020, some historically advantaged socioeconomic groups such as those …
It is unclear how the COVID-19 pandemic impacted human papillomavirus (HPV) vaccine uptake and which sociodemographic groups m …
Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia.
Day D, Grech L, Nguyen M, Bain N, Kwok A, Harris S, Chau H, Chan B, Blennerhassett R, Nott L, Hamad N, Tognela A, Hoffman D, McCartney A, Webber K, Wong J, Underhill C, Sillars B, Winkel A, Savage M, Loe BS, Freeman D, Segelov E, On Behalf Of The Canvaccs Diabvaccs And Msvaccs Investigators. Day D, et al. Vaccines (Basel). 2022 May 26;10(6):851. doi: 10.3390/vaccines10060851. Vaccines (Basel). 2022. PMID: 35746458 Free PMC article.
The survey evaluated sociodemographic and disease-related characteristics and incorporated three validated scales measuring vaccine hesitancy and vaccine-related beliefs generally and specific to their disease: the Oxford COVID-19 Vaccine Hesitancy Sca …
The survey evaluated sociodemographic and disease-related characteristics and incorporated three validated scales measuring vaccine h …
Individual-level factors associated with COVID-19 vaccine acceptance among U.S. patients with cancer.
Hathaway CA, Siegel EM, Gonzalez BD, Oswald LB, Peoples AR, Ulrich CM, Penedo FJ, Tworoger SS, Islam JY. Hathaway CA, et al. Vaccine. 2022 Nov 2;40(46):6649-6657. doi: 10.1016/j.vaccine.2022.09.063. Epub 2022 Sep 28. Vaccine. 2022. PMID: 36210253 Free PMC article.
Cancer patients are especially vulnerable to adverse COVID-19 outcomes and require targeted prevention efforts against COVID-19. ...Patients with confirmed invasive cancer diagnosis through Cancer Registry data were asked about vaccine ac
Cancer patients are especially vulnerable to adverse COVID-19 outcomes and require targeted prevention efforts against COVI
Therapeutic targets and functions of curcumol against COVID-19 and colon adenocarcinoma.
Li J, Peng P, Lai KP. Li J, et al. Front Nutr. 2022 Jul 29;9:961697. doi: 10.3389/fnut.2022.961697. eCollection 2022. Front Nutr. 2022. PMID: 35967794 Free PMC article.
Since 2019, the coronavirus disease (COVID-19) has caused 6,319,395 deaths worldwide. Although the COVID-19 vaccine is currently available, the latest variant of the virus, Omicron, spreads more easily than earlier strains, and its mortality rate is still hig …
Since 2019, the coronavirus disease (COVID-19) has caused 6,319,395 deaths worldwide. Although the COVID-19 vaccine is …
COVID-19 Vaccination Status and Hesitancy among Breast Cancer Patients after Two Years of Pandemic: A Cross-Sectional Survey.
Liu W, Wu Y, Yang R, Chen R, Huang Y, Zhao X, Xie M, Li Q, Wang Q, Chen J. Liu W, et al. Vaccines (Basel). 2022 Sep 15;10(9):1530. doi: 10.3390/vaccines10091530. Vaccines (Basel). 2022. PMID: 36146608 Free PMC article.
RESULTS: Among the 1132 participants, 55.2% had received a COVID-19 vaccine. The incidence of adverse events per dose was around 40%. Vaccine hesitancy of 61.9% was observed among patients who had not fully received three doses of vaccine or boosters. …
RESULTS: Among the 1132 participants, 55.2% had received a COVID-19 vaccine. The incidence of adverse events per dose was arou …
Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer.
Gong IY, Vijenthira A, Powis M, Calzavara A, Patrikar A, Sutradhar R, Hicks LK, Wilton D, Singh S, Krzyzanowska MK, Cheung MC. Gong IY, et al. JAMA Oncol. 2022 Dec 29. doi: 10.1001/jamaoncol.2022.6815. Online ahead of print. JAMA Oncol. 2022. PMID: 36580318
IMPORTANCE: Patients with cancer are known to have increased risk of COVID-19 complications, including death. ...COVID-19 severe outcomes (composite of hospitalization and death) were significantly higher in patients with cancer compared to patients wi …
IMPORTANCE: Patients with cancer are known to have increased risk of COVID-19 complications, including death. ...COVID- …
COVID-19 Concerns, Vaccine Acceptance and Trusted Sources of Information among Patients Cared for in a Safety-Net Health System.
Davis TC, Beyl R, Bhuiyan MAN, Davis AB, Vanchiere JA, Wolf MS, Arnold CL. Davis TC, et al. Vaccines (Basel). 2022 Jun 10;10(6):928. doi: 10.3390/vaccines10060928. Vaccines (Basel). 2022. PMID: 35746535 Free PMC article.
We examined COVID-19 concerns, vaccine acceptance, and trusted sources of information among patients in a safety-net health system in Louisiana. ...Overall, participants reported that physicians were the most trusted source of COVID-19 vaccine informat …
We examined COVID-19 concerns, vaccine acceptance, and trusted sources of information among patients in a safety-net health sy …
Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center.
Brunello A, Guarneri V, Coppola M, Bernardi M, Ottolitri K, Ghi MG, Mioranza E, Vianello F, Gottardi M, Lonardi S, Zagonel V. Brunello A, et al. Oncologist. 2022 Mar 4;27(2):e203-e205. doi: 10.1093/oncolo/oyab037. Oncologist. 2022. PMID: 35641217 Free PMC article.
BACKGROUND: Few data are available on the safety of COVID-19 vaccines in cancer patients undergoing active cancer-directed treatment. PATIENTS AND METHODS: This case series analyzes outcomes in terms of adverse events in 5297 patients undergoing anti-cance
BACKGROUND: Few data are available on the safety of COVID-19 vaccines in cancer patients undergoing active cancer-direc …
Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients.
Heudel P, Favier B, Solodky ML, Assaad S, Chaumard N, Tredan O, Bachelot T, Ray-Coquard I, Russias B, Fournier ML, Mastroianni B, Avrillon V, Michallet AS, Zrounba P, Chabaud S, Perol D, Blay JY. Heudel P, et al. Eur J Cancer. 2022 Apr;165:174-183. doi: 10.1016/j.ejca.2022.01.035. Epub 2022 Feb 10. Eur J Cancer. 2022. PMID: 35245864 Free PMC article.
BACKGROUND: Patients with cancer are at high risk of severe or lethal COVID-19. The impact of SARS-COV-2 vaccination on the risk of developing COVID-19 was investigated in an exhaustive series of patients from a comprehensive cancer center. ...Independ …
BACKGROUND: Patients with cancer are at high risk of severe or lethal COVID-19. The impact of SARS-COV-2 vaccination on the ri …
COVID-19 vaccine associated cervical lymphadenopathy: a case series.
Heaven CL, Barber L, Ahmadi O, Selvarajah K, Shetty S. Heaven CL, et al. ANZ J Surg. 2022 Sep;92(9):2286-2291. doi: 10.1111/ans.17808. Epub 2022 Jun 10. ANZ J Surg. 2022. PMID: 35588265 Free PMC article.
RESULTS: All patients were identified to have cervical lymphadenopathy on radiological imaging and a recent history of COVID-19 vaccination with the Pfizer BioNTech vaccine. Interval vaccination to fine needle aspiration time ranged between 41 and 76 days. All patie …
RESULTS: All patients were identified to have cervical lymphadenopathy on radiological imaging and a recent history of COVID-19 vacci …
CD4+ T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses.
Woldemeskel BA, Dykema AG, Garliss CC, Cherfils S, Smith KN, Blankson JN. Woldemeskel BA, et al. J Clin Invest. 2022 Mar 1;132(5):e156083. doi: 10.1172/JCI156083. J Clin Invest. 2022. PMID: 35061630 Free PMC article. Clinical Trial.
Our results showed that S815-827 was recognized by 42% of vaccinated participants in our study who received the Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) COVID-19 vaccines. Using T cell expansion and T cell receptor sequencing assays, we demonstrated that S815-827- …
Our results showed that S815-827 was recognized by 42% of vaccinated participants in our study who received the Pfizer-BioNTech (BNT162b2) o …
COVID-19 vaccination in patients with cancer, a rapid review.
Chehade L, Zeitoun J, Lombe D, Irshad S, Hemelrijck MV, Canfell K, Sullivan R, Mukherji D. Chehade L, et al. Ecancermedicalscience. 2022 Feb 16;16:1355. doi: 10.3332/ecancer.2022.1355. eCollection 2022. Ecancermedicalscience. 2022. PMID: 35510135 Free PMC article.
This review aims to summarise the current data for COVID-19 vaccine efficacy in patients with cancer, suggest priority areas for future research and look at potential disparities at a global level. Although patients diagnosed with or receiving therapy for …
This review aims to summarise the current data for COVID-19 vaccine efficacy in patients with cancer, suggest priority …
Ipsilateral Malignant Axillary Lymphadenopathy and Contralateral Reactive Lymph Nodes in a COVID-19 Vaccine Recipient With Breast Cancer.
Adin ME, Wu J, Isufi E, Tsui E, Pucar D. Adin ME, et al. J Breast Cancer. 2022 Apr;25(2):140-144. doi: 10.4048/jbc.2022.25.e12. Epub 2021 Mar 15. J Breast Cancer. 2022. PMID: 35380021 Free PMC article.
Vaccine-related axillary nodal enlargement is a common benign condition that many mRNA vaccine receivers experience. However, a false attribution of axillary swelling to vaccination may result in delay in cancer care and potential disease progression, particu
Vaccine-related axillary nodal enlargement is a common benign condition that many mRNA vaccine receivers experience. However,
Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in Spain.
Mallah N, Pardo-Seco J, López-Pérez LR, González-Pérez JM, Rosón B, Otero-Barrós MT, Durán-Parrondo C, Nartallo-Penas V, Mirás-Carballal S, Rodríguez-Tenreiro C, Rivero-Calle I, Gómez-Carballa A, Salas A, Martinón-Torres F. Mallah N, et al. Environ Res. 2022 Dec;215(Pt 2):114252. doi: 10.1016/j.envres.2022.114252. Epub 2022 Sep 10. Environ Res. 2022. PMID: 36096168 Free PMC article.
BACKGROUND: Research on the effectiveness of COVID-19 booster-based vaccine schedule is ongoing and real-world data on vaccine effectiveness (VE) in comorbid patients are limited. ...CONCLUSIONS: A booster dose of COVID-19 vaccine increases the …
BACKGROUND: Research on the effectiveness of COVID-19 booster-based vaccine schedule is ongoing and real-world data on vacc
Safety and Tolerability of COVID-19 Vaccines in Patients with Cancer: A Single Center Retrospective Analysis.
Nuzzo A, Manacorda S, Sammarco E, Sbrana A, Bazzurri S, Paolieri F, Manfredi F, Mercinelli C, Ferrari M, Massaro G, Bonato A, Salfi A, Galli L, Morganti R, Antonuzzo A, Cremolini C, Masi G. Nuzzo A, et al. Vaccines (Basel). 2022 Jun 2;10(6):892. doi: 10.3390/vaccines10060892. Vaccines (Basel). 2022. PMID: 35746500 Free PMC article.
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 disease (COVID-19) has caused a worldwide challenging and threatening pandemic. ...Vaccine-related adverse events were recorded using a face-to-face questionnaire including a toxicity grading scale. ...
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 disease (COVID-19) has caused a worldwide challenging and threatening pan …
COVID-19 Vaccine Hesitancy in Australian Patients with Solid Organ Cancers.
Bain N, Nguyen M, Grech L, Day D, McCartney A, Webber K, Kwok A, Harris S, Chau H, Chan B, Nott L, Hamad N, Tognela A, Underhill C, Loe BS, Freeman D, Segelov E, On Behalf Of The Canvaccs Investigators. Bain N, et al. Vaccines (Basel). 2022 Aug 23;10(9):1373. doi: 10.3390/vaccines10091373. Vaccines (Basel). 2022. PMID: 36146450 Free PMC article.
Perceptions and beliefs regarding COVID-19 vaccination were assessed using the Oxford COVID-19 Vaccine Hesitancy Scale, the Oxford COVID-19 Vaccine Confidence and Complacency Scale and the Disease Influenced Vaccine Acceptance Scale-6. .. …
Perceptions and beliefs regarding COVID-19 vaccination were assessed using the Oxford COVID-19 Vaccine Hesitancy Scale, …
Religiosity and Beliefs toward COVID-19 Vaccination among Adults in Puerto Rico.
López-Cepero A, Rodríguez M, Joseph V, Suglia SF, Colón-López V, Toro-Garay YG, Archevald-Cansobre MD, Fernández-Repollet E, Pérez CM. López-Cepero A, et al. Int J Environ Res Public Health. 2022 Sep 17;19(18):11729. doi: 10.3390/ijerph191811729. Int J Environ Res Public Health. 2022. PMID: 36141998 Free PMC article.
Compared to individuals rating religiosity as 'less important' to them, those rating it as 'very important' were more likely to be unwilling or uncertain to get the COVID-19 vaccine (PR = 1.51, 95% CI = 1.10-2.05). Higher ratings of importance of religiosity, compar …
Compared to individuals rating religiosity as 'less important' to them, those rating it as 'very important' were more likely to be unwilling …
Diagnostic pitfalls after COVID-19 vaccination in melanoma and breast cancer patients: A case series.
de Bock E, Trumpi K, Suijkerbuijk KPM, Vriens MR, Richir MC. de Bock E, et al. Int J Surg Case Rep. 2022 Apr;93:106938. doi: 10.1016/j.ijscr.2022.106938. Epub 2022 Mar 12. Int J Surg Case Rep. 2022. PMID: 35298983 Free PMC article.
PRESENTATION OF CASES: This case series describes seven patients diagnosed with melanoma or breast cancer in whom lymphadenopathy was observed on oncology imaging after COVID-19 vaccination. ...Abnormal lymph nodes could be observed up to sixty-nine days after CO
PRESENTATION OF CASES: This case series describes seven patients diagnosed with melanoma or breast cancer in whom lymphadenopathy was …
Prevalence and Assessment of Factors Associated with COVID-19 Vaccine Hesitancy in an Ethnic Minority Oncology Patient Population.
Lee M, Miao E, Rapkin B, Halmos B, Shankar V, Goel S. Lee M, et al. Vaccines (Basel). 2022 Oct 14;10(10):1711. doi: 10.3390/vaccines10101711. Vaccines (Basel). 2022. PMID: 36298576 Free PMC article.
Overall, there was a significantly higher chance of being vaccinated if patients were receiving active cancer treatment, believed COVID-19 was harmful, or that the vaccine was safe, and knew COVID-19 was a virus. ...However, we also discovered various …
Overall, there was a significantly higher chance of being vaccinated if patients were receiving active cancer treatment, believed …
The Prevalence of COVID-19 Vaccination and Vaccine Hesitancy in Pregnant Women: An Internet-based Cross-sectional Study in Japan.
Hosokawa Y, Okawa S, Hori A, Morisaki N, Takahashi Y, Fujiwara T, Nakayama SF, Hamada H, Satoh T, Tabuchi T. Hosokawa Y, et al. J Epidemiol. 2022 Apr 5;32(4):188-194. doi: 10.2188/jea.JE20210458. Epub 2022 Feb 11. J Epidemiol. 2022. PMID: 35095091 Free PMC article.
Multivariate Poisson regression analysis was used to investigate the factors contributing to vaccine hesitancy. RESULTS: The prevalence of vaccination and vaccine hesitancy among pregnant women was 13.4% (n = 217) and 50.9% (n = 825), respectively. ...Other factors, …
Multivariate Poisson regression analysis was used to investigate the factors contributing to vaccine hesitancy. RESULTS: The prevalen …
Mucosal delivery of nanovaccine strategy against COVID-19 and its variants.
Lee J, Khang D. Lee J, et al. Acta Pharm Sin B. 2022 Nov 21. doi: 10.1016/j.apsb.2022.11.022. Online ahead of print. Acta Pharm Sin B. 2022. PMID: 36438851 Free PMC article. Review.
Including COVID-19 vaccines that are licensed for human use, most of the vaccines that are currently in clinical trials are administered via parenteral route. However, it has been proven that the parenteral vaccines do not induce localized immunity in the upper respiratory …
Including COVID-19 vaccines that are licensed for human use, most of the vaccines that are currently in clinical trials are administe …
Racial and Ethnic Variation in COVID-19 Vaccination Uptake Among Medicare Beneficiaries with Cancer History.
Poghosyan H, Dinan MA, Tamamyan G, Nelson L, Jeon S. Poghosyan H, et al. J Racial Ethn Health Disparities. 2022 Sep 23:1-9. doi: 10.1007/s40615-022-01415-2. Online ahead of print. J Racial Ethn Health Disparities. 2022. PMID: 36149576 Free PMC article.
BACKGROUND: The purpose of this study was to estimate COVID-19 vaccination rate among Medicare beneficiaries with cancer history and determine whether COVID-19 vaccine uptake is higher among non-Hispanic White beneficiaries compared with racially and e …
BACKGROUND: The purpose of this study was to estimate COVID-19 vaccination rate among Medicare beneficiaries with cancer histo …
Vaccine hesitancy in the post-vaccination COVID-19 era: a machine learning and statistical analysis driven study.
Gupta H, Verma OP. Gupta H, et al. Evol Intell. 2022 Mar 9:1-19. doi: 10.1007/s12065-022-00704-3. Online ahead of print. Evol Intell. 2022. PMID: 35281291 Free PMC article.
Background The COVID-19 pandemic has badly affected people of all ages globally. ...Also, the chi-square (statistical), LR, RF, and LGBM have been utilized to estimate the most probable attribute in the dataset that resulted in death, hospitalization, and COVID-19. …
Background The COVID-19 pandemic has badly affected people of all ages globally. ...Also, the chi-square (statistical), LR, RF, and L …
Accelerating clinical trial development in vaccinology: COVID-19 and beyond.
Corey L, Miner MD. Corey L, et al. Curr Opin Immunol. 2022 Jun;76:102206. doi: 10.1016/j.coi.2022.102206. Epub 2022 Apr 20. Curr Opin Immunol. 2022. PMID: 35569415 Free PMC article. Review.
The remarkable success of the US government-backed COVID-19 vaccine development in 2020 offers several lessons on how to effectively foster rapid vaccine discovery and development. Conceptually, the formation of a public-private partnership that included inno …
The remarkable success of the US government-backed COVID-19 vaccine development in 2020 offers several lessons on how to effec …
Perceptions and tolerance of uncertainty: relationship to trust in COVID-19 health information and vaccine hesitancy.
Gillman AS, Scharnetzki L, Boyd P, Ferrer RA, Klein WMP, Han PKJ. Gillman AS, et al. J Behav Med. 2022 Apr 8:1-14. doi: 10.1007/s10865-022-00302-9. Online ahead of print. J Behav Med. 2022. PMID: 35394240 Free PMC article.
In a national sample of US adults in May-June 2020, we examined how both perceptions of uncertainty about COVID-19 and trait-level differences in tolerance of uncertainty arising from various sources (risk, ambiguity, and complexity) are related to vaccine hesitancy …
In a national sample of US adults in May-June 2020, we examined how both perceptions of uncertainty about COVID-19 and trait-level di …
Primary care practice and cancer suspicion during the first three COVID-19 lockdowns in the UK: a qualitative study.
Smith CF, Nicholson BD, Hirst Y, Fleming S, Bankhead CR. Smith CF, et al. Br J Gen Pract. 2022 Jul 22;72(723):e713-21. doi: 10.3399/BJGP.2021.0719. Online ahead of print. Br J Gen Pract. 2022. PMID: 35940883 Free PMC article.
BACKGROUND: The COVID-19 pandemic has profoundly affected UK primary care, and as a result the route to cancer diagnosis for many patients. ...This combined with usual winter pressures, demands of the vaccine programme, and surging levels of COVID-19 m …
BACKGROUND: The COVID-19 pandemic has profoundly affected UK primary care, and as a result the route to cancer diagnosis for m …
COVID-19 Vaccine-Associated Subclinical Axillary Lymphadenopathy on Screening Mammogram.
Raj S, Ogola G, Han J. Raj S, et al. Acad Radiol. 2022 Apr;29(4):501-507. doi: 10.1016/j.acra.2021.11.010. Epub 2021 Nov 17. Acad Radiol. 2022. PMID: 34906409 Free PMC article.
Incidence of unilateral axillary sLAD was significantly higher (p-value<0.01) in those who received a COVID-19 vaccination within approximately 7 weeks preceding screening mammogram. 13.2% of patients who received the Pfizer vaccine and 9.5% of patients who recei …
Incidence of unilateral axillary sLAD was significantly higher (p-value<0.01) in those who received a COVID-19 vaccination within …
COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity.
Lee MH, Kim BJ. Lee MH, et al. J Microbiol. 2022 Mar;60(3):321-334. doi: 10.1007/s12275-022-1621-2. Epub 2022 Feb 14. J Microbiol. 2022. PMID: 35157221 Free PMC article. Review.
Severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) infection, which causes coronavirus disease 2019 (COVID-19), has led to many cases and deaths worldwide. Therefore, a number of vaccine candidates have been developed to control the COVID-19 p …
Severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) infection, which causes coronavirus disease 2019 (COVID-19), has l …
Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report.
Tripathy S, Alvarez N, Jaiswal S, Williams R, Al-Khadimi M, Hackman S, Phillips W, Kaur S, Cervantez S, Kelly W, Taverna J. Tripathy S, et al. J Med Case Rep. 2022 Nov 25;16(1):445. doi: 10.1186/s13256-022-03660-9. J Med Case Rep. 2022. PMID: 36434709 Free PMC article.
BACKGROUND: Given the current climate of the pandemic, lung cancer patients are especially vulnerable to complications from severe acute respiratory syndrome coronavirus 2 infection. ...In recent years, immunotherapy has taken a preeminent role in the treatment of non-smal …
BACKGROUND: Given the current climate of the pandemic, lung cancer patients are especially vulnerable to complications from severe ac …
COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein.
Lee J, Kim J, Kang J, Lee HJ. Lee J, et al. J Pharm Investig. 2022 Oct 26:1-22. doi: 10.1007/s40005-022-00596-6. Online ahead of print. J Pharm Investig. 2022. PMID: 36320434 Free PMC article. Review.
AREA COVERED: Pharmacological approaches including drug repositioning have been a priority for initial COVID-19 therapy due to the time-consuming nature of the vaccine development process. ...In this review, we evaluated the interaction of current COVID-19 dr …
AREA COVERED: Pharmacological approaches including drug repositioning have been a priority for initial COVID-19 therapy due to the ti …
Axillary Lymphadenopathy Associated With COVID-19 Vaccination: Updates and Recommendations.
Schwaner SL. Schwaner SL. J Radiol Nurs. 2022 Dec;41(4):309-312. doi: 10.1016/j.jradnu.2022.08.006. Epub 2022 Aug 19. J Radiol Nurs. 2022. PMID: 35999889 Free PMC article. Review.
In the past this was a limited finding, primarily documented in association with smallpox and H1N1 vaccination.The advent of the novel mRNA vaccine for COVID-19 in December of 2021, and subsequent large scale vaccination effort, has resulted in a marked increase in …
In the past this was a limited finding, primarily documented in association with smallpox and H1N1 vaccination.The advent of the novel mRNA …
COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective.
Marcelin JR, Pettifor A, Janes H, Brown ER, Kublin JG, Stephenson KE. Marcelin JR, et al. Open Forum Infect Dis. 2022 Mar 10;9(5):ofac124. doi: 10.1093/ofid/ofac124. eCollection 2022 May. Open Forum Infect Dis. 2022. PMID: 35493113 Free PMC article. Review.
Newer variants have revealed less vaccine protection against infection and attenuation of vaccine effects on transmission. COVID-19 vaccines still likely reduce transmission compared with not being vaccinated at all, even with variants of concern; however, de …
Newer variants have revealed less vaccine protection against infection and attenuation of vaccine effects on transmission. …
Letter to the Editor: Perspectives on mRNA Vaccine Development for Cancer.
Ke Y. Ke Y. J Interferon Cytokine Res. 2022 Nov;42(11):592-593. doi: 10.1089/jir.2022.0145. Epub 2022 Sep 15. J Interferon Cytokine Res. 2022. PMID: 36112111
Cancer progression is significantly associated with immune response, and mRNA vaccine also shows obvious advantages for cancer immunotherapy. In this study, we briefly summarize the recent advances and discuss the perspectives on tumor mRNA vaccine dev
Cancer progression is significantly associated with immune response, and mRNA vaccine also shows obvious advantages for can
Ultrasound Features to Differentiate COVID-19 Vaccine-Induced Benign Adenopathy from Breast Cancer Related Malignant Adenopathy.
Hl C, Gj W, Jwt L, J S, Lp M, Ht LP. Hl C, et al. Acad Radiol. 2022 Jul;29(7):1004-1012. doi: 10.1016/j.acra.2022.02.015. Epub 2022 Feb 21. Acad Radiol. 2022. PMID: 35296413 Free PMC article.
RATIONALE AND OBJECTIVE: To identify nodal features used to distinguish coronavirus disease 2019 (COVID-19) vaccine-Induced benign reactive adenopathy from malignant adenopathy. MATERIALS AND METHODS: This IRB-approved, single-institution, retrospective study compar …
RATIONALE AND OBJECTIVE: To identify nodal features used to distinguish coronavirus disease 2019 (COVID-19) vaccine-Induced be …
Sociopolitical, mental health, and sociodemographic correlates of COVID-19 vaccine hesitancy among young adults in 6 US metropolitan areas.
Klinkhammer KE, Romm KF, Kerrigan D, McDonnell KA, Vyas A, Wang Y, Ma Y, Berg CJ. Klinkhammer KE, et al. Prev Med Rep. 2022 Jun;27:101812. doi: 10.1016/j.pmedr.2022.101812. Epub 2022 May 6. Prev Med Rep. 2022. PMID: 35541217 Free PMC article.
Given the need to increase COVID-19 vaccine uptake among US young adults, we examined the extent of COVID-19 vaccine hesitancy in this population and related factors. We analyzed Fall 2020 survey data from 2,453 young adults (ages 18-34) across 6 US me …
Given the need to increase COVID-19 vaccine uptake among US young adults, we examined the extent of COVID-19 vaccine
The Effects of an mRNA Covid-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans.
Frankel AE, Capozzola T, Andrabi R, Ahn C, Zhou P, He WT, Burton DR. Frankel AE, et al. Med Res Arch. 2022 Jul 31;10(7):10.18103/mra.v10i7.2932. doi: 10.18103/mra.v10i7.2932. Med Res Arch. 2022. PMID: 36405515 Free PMC article.
Serum antibodies to SARS-CoV-2 spike protein are important markers of protection against COVID-19 disease. We evaluated total and neutralizing antibody levels pre and post third booster vaccine and compared responses among different cancer-bearing and healthy …
Serum antibodies to SARS-CoV-2 spike protein are important markers of protection against COVID-19 disease. We evaluated total and neu …
Attitudes Towards COVID-19 Vaccine: A Survey of Health Care Workers in Oman.
Khamis F, Badahdah A, Al Mahyijari N, Al Lawati F, Al Noamani J, Al Salmi I, Al Bahrani M. Khamis F, et al. J Epidemiol Glob Health. 2022 Mar;12(1):1-6. doi: 10.1007/s44197-021-00018-0. Epub 2021 Dec 20. J Epidemiol Glob Health. 2022. PMID: 34928489 Free PMC article.
Coronavirus Disease 2019 (COVID-19) vaccine hesitancy among health care workers (HCWs) is widely reported. ...Forty percent of HCWs were willing to uptake the COVID-19 vaccines. Physicians and male HCWs had more positive attitudes toward the COVID-19 v …
Coronavirus Disease 2019 (COVID-19) vaccine hesitancy among health care workers (HCWs) is widely reported. ...Forty percent of …
Brain tumor patients and COVID-19 vaccines: results of an international survey.
Voisin MR, Oliver K, Farrimond S, Chee T, O'Halloran P, Glas M; International Brain Tumour Alliance (IBTA) Senior Advisors; Zadeh G. Voisin MR, et al. Neurooncol Adv. 2022 May 3;4(1):vdac063. doi: 10.1093/noajnl/vdac063. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35707317 Free PMC article.
The purpose of this study was to determine if brain tumor patients and their caregivers have received a COVID-19 vaccine, and explore their thoughts and opinions on these vaccines. ...Less than 10% of patients decided against receiving a vaccination against COVID
The purpose of this study was to determine if brain tumor patients and their caregivers have received a COVID-19 vaccine, and …
mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients.
Albiol N, Aso O, Gómez-Pérez L, Triquell M, Roch N, Lázaro E, Esquirol A, González I, López-Contreras J, Sierra J, Martino R, García-Cadenas I. Albiol N, et al. Support Care Cancer. 2022 Dec;30(12):9687-9690. doi: 10.1007/s00520-022-07376-w. Epub 2022 Sep 28. Support Care Cancer. 2022. PMID: 36169731 Free PMC article.
PURPOSE: This study aims to describe the incidence and severity of adverse events (AEs) following the mRNA-1273 SARS-CoV-2 vaccine and explore the risk perception of COVID-19 in allogeneic hematopoietic stem cell transplant (HCT) recipients. ...Female sex (OR 3.94, …
PURPOSE: This study aims to describe the incidence and severity of adverse events (AEs) following the mRNA-1273 SARS-CoV-2 vaccine an …
Infection and reinfection with SARS-CoV-2 in cancer patients: A cohort study.
Nitipir C, Parosanu AI, Olaru M, Popa AM, Pirlog C, Iaciu C, Vrabie R, Stanciu MI, Oprescu-Macovei A, Bumbacea D, Negrei C, Orlov-Slavu C. Nitipir C, et al. Exp Ther Med. 2022 Jun;23(6):399. doi: 10.3892/etm.2022.11326. Epub 2022 Apr 15. Exp Ther Med. 2022. PMID: 35619634 Free PMC article.
COVID-19 reinfection, although a controversial issue, is an important clinical problem in cancer patients and beyond. The present study aimed to identify the risk factors associated with worse outcomes in cancer patients with Covid-19 in both first inf
COVID-19 reinfection, although a controversial issue, is an important clinical problem in cancer patients and beyond. The pres
No apparent association between mRNA COVID-19 vaccination and venous thromboembolism.
Nicholson M, Goubran H, Chan N, Siegal D. Nicholson M, et al. Blood Rev. 2022 Nov;56:100970. doi: 10.1016/j.blre.2022.100970. Epub 2022 May 11. Blood Rev. 2022. PMID: 35577626 Free PMC article. Review.
By January 2022 over ten billion doses of COVID-19 vaccines had been administered worldwide. Concerns about COVID-19 vaccine-associated thrombosis arose after the characterization of a rare prothrombotic condition associated with adenoviral vector-based CO
By January 2022 over ten billion doses of COVID-19 vaccines had been administered worldwide. Concerns about COVID-19 vaccin
mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks and Coverage.
Nashwan A, Yassin M, Soliman A, De Sanctis V, Ibrahim M. Nashwan A, et al. Acta Biomed. 2022 Jul 1;93(3):e2022236. doi: 10.23750/abm.v93i3.13103. Acta Biomed. 2022. PMID: 35775753 Free PMC article. Review.
The number of COVID-19 vaccine-rich countries that have started COVID-19 third-dose booster programs is growing dramatically despite the lack of robust evidence on the effectiveness, safety, and frequency of the required booster doses that makes the individua …
The number of COVID-19 vaccine-rich countries that have started COVID-19 third-dose booster programs is growing dramati …
Corticosteroid Use in Otolaryngology: Current Considerations During the COVID-19 Era.
Chang CWD, McCoul ED, Briggs SE, Guardiani EA, Durand ML, Hadlock TA, Hillel AT, Kattar N, Openshaw PJM, Osazuwa-Peters N, Poetker DM, Shin JJ, Chandrasekhar SS, Bradford CR, Brenner MJ. Chang CWD, et al. Otolaryngol Head Neck Surg. 2022 Nov;167(5):803-820. doi: 10.1177/01945998211064275. Epub 2021 Dec 7. Otolaryngol Head Neck Surg. 2022. PMID: 34874793 Review.
OBJECTIVE: To offer pragmatic, evidence-informed advice on administering corticosteroids in otolaryngology during the coronavirus disease 2019 (COVID-19) pandemic, considering therapeutic efficacy, potential adverse effects, susceptibility to COVID-19, and potential …
OBJECTIVE: To offer pragmatic, evidence-informed advice on administering corticosteroids in otolaryngology during the coronavirus disease 20 …
Adaptation and Dissemination of a National Cancer Institute HPV Vaccine Evidence-Based Cancer Control Program to the Social Media Messaging Environment.
Hopfer S, Phillips KK, Weinzierl M, Vasquez HE, Alkhatib S, Harabagiu SM. Hopfer S, et al. Front Digit Health. 2022 Jul 27;4:819228. doi: 10.3389/fdgth.2022.819228. eCollection 2022. Front Digit Health. 2022. PMID: 35966142 Free PMC article.
Yet, a gap remains on how to adapt evidence-based vaccine interventions for the in vivo competitive social media messaging environment and what strategies to employ to make vaccine messages go viral. Push-pull and RE-AIM dissemination frameworks guided our adaptatio …
Yet, a gap remains on how to adapt evidence-based vaccine interventions for the in vivo competitive social media messaging environmen …
Use of remdesivir for COVID-19 in patients with hematologic cancer.
Martin-Onraët A, Barrientos-Flores C, Vilar-Compte D, Pérez-Jimenez C, Alatorre-Fernandez P. Martin-Onraët A, et al. Clin Exp Med. 2022 Dec 12:1-8. doi: 10.1007/s10238-022-00964-4. Online ahead of print. Clin Exp Med. 2022. PMID: 36508048 Free PMC article.
Fifty-two percent had non-Hodgkin lymphoma. Fifty patients (44%) had at least two doses of SARS-CoV-2 vaccine. COVID-19 was classified as mild (52.6%), moderate (9.7%), and severe/critical (28%). ...Nine patients received remdesivir at the ambulatory clinic (33%), t …
Fifty-two percent had non-Hodgkin lymphoma. Fifty patients (44%) had at least two doses of SARS-CoV-2 vaccine. COVID-19 was cl …
Dynamic assessment of the COVID-19 vaccine acceptance leveraging social media data.
Li L, Zhou J, Ma Z, Bensi MT, Hall MA, Baecher GB. Li L, et al. J Biomed Inform. 2022 May;129:104054. doi: 10.1016/j.jbi.2022.104054. Epub 2022 Mar 21. J Biomed Inform. 2022. PMID: 35331966 Free PMC article.
Prior studies have applied survey techniques to investigate vaccine acceptance, but these may be slow and expensive. This study investigates 29 million vaccine-related tweets from August 8, 2020 to April 19, 2021 and proposes a social media-based approach that deriv …
Prior studies have applied survey techniques to investigate vaccine acceptance, but these may be slow and expensive. This study inves …
SARS-CoV-2 vaccine acceptability among caregivers of childhood cancer survivors.
Wimberly CE, Towry L, Davis E, Johnston EE, Walsh KM. Wimberly CE, et al. Pediatr Blood Cancer. 2022 Jun;69(6):e29443. doi: 10.1002/pbc.29443. Epub 2021 Nov 17. Pediatr Blood Cancer. 2022. PMID: 34786824 Free PMC article.
Qualitative analysis of free-text responses revealed three general themes, including (a) confidence in science, medicine, and vaccination as a strategy for health promotion, (b) confidence in SARS-CoV-2 vaccination and belief that CCS are at greater risk of COVID-19 compli …
Qualitative analysis of free-text responses revealed three general themes, including (a) confidence in science, medicine, and vaccination as …
An Assessment of the Bivalent Vaccine as a Second Booster for COVID-19.
Gupta SL, Jaiswal RK. Gupta SL, et al. Vaccines (Basel). 2022 Dec 29;11(1):79. doi: 10.3390/vaccines11010079. Vaccines (Basel). 2022. PMID: 36679924 Free PMC article.
In the USA, two monovalent COVID-19 mRNA vaccines are primarily used for vaccination [...]....
In the USA, two monovalent COVID-19 mRNA vaccines are primarily used for vaccination [...]....
Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination.
Horvat JV, Sevilimedu V, Becker AS, Perez-Johnston R, Yeh R, Feigin KN. Horvat JV, et al. Eur Radiol. 2022 Aug;32(8):5752-5758. doi: 10.1007/s00330-022-08655-0. Epub 2022 Mar 5. Eur Radiol. 2022. PMID: 35247087 Free PMC article.
OBJECTIVES: To assess the frequency of ipsilateral axillary adenopathy on breast MRI after COVID-19 vaccination. To investigate the duration, outcomes, and associated variables of vaccine-related adenopathy. ...CONCLUSIONS: Vaccine-related adenopathy is a fre …
OBJECTIVES: To assess the frequency of ipsilateral axillary adenopathy on breast MRI after COVID-19 vaccination. To investigate the d …
Role of literacy, fear and hesitancy on acceptance of COVID-19 vaccine among village health volunteers in Thailand.
Siewchaisakul P, Sarakarn P, Nanthanangkul S, Longkul J, Boonchieng W, Wungrath J. Siewchaisakul P, et al. PLoS One. 2022 Jun 24;17(6):e0270023. doi: 10.1371/journal.pone.0270023. eCollection 2022. PLoS One. 2022. PMID: 35749368 Free PMC article.
BACKGROUND: The roles of literacy, fear and hesitancy were investigated for acceptance of COVID-19 vaccine (AV) types among village health volunteers (VHVs) in Thailand. ...The questionnaire was developed based on the HLVa-IT (Health Literacy Vaccinale degli adulti …
BACKGROUND: The roles of literacy, fear and hesitancy were investigated for acceptance of COVID-19 vaccine (AV) types among vi …
A single immunization with cellular vaccine confers dual protection against SARS-CoV-2 and cancer.
Shimizu K, Ueda S, Kawamura M, Satoh M, Fujii SI. Shimizu K, et al. Cancer Sci. 2022 Aug;113(8):2536-2547. doi: 10.1111/cas.15434. Epub 2022 Jun 7. Cancer Sci. 2022. PMID: 35598170 Free PMC article.
The efficacy of current coronavirus disease 2019 (COVID-19) vaccines has been demonstrated; however, emerging evidence suggests insufficient protection in certain immunocompromised cancer patients. ...These findings suggest aAVC-TAA/CoV-2-S therapy as a promising …
The efficacy of current coronavirus disease 2019 (COVID-19) vaccines has been demonstrated; however, emerging evidence suggests insuf …
Geographic Heterogeneity in Behavioral and Social Drivers of COVID-19 Vaccination.
Masters NB, Zhou T, Meng L, Lu PJ, Kriss JL, Black C, Omari A, Boone K, Weiss D, Carter RJ, Brewer NT, Singleton JA. Masters NB, et al. Am J Prev Med. 2022 Dec;63(6):883-893. doi: 10.1016/j.amepre.2022.06.016. Epub 2022 Jul 20. Am J Prev Med. 2022. PMID: 36404022 Free PMC article.
RESULTS: National coverage with at least 1 dose of COVID-19 vaccine was 79.3% by December 2021, with substantial geographic heterogeneity. ...Both regions had similar temporal trends regarding concerns about COVID-19 and confidence in vaccine importanc …
RESULTS: National coverage with at least 1 dose of COVID-19 vaccine was 79.3% by December 2021, with substantial geographic he …
Emerging vaccine nanotechnology: From defense against infection to sniping cancer.
Feng C, Li Y, Ferdows BE, Patel DN, Ouyang J, Tang Z, Kong N, Chen E, Tao W. Feng C, et al. Acta Pharm Sin B. 2022 May;12(5):2206-2223. doi: 10.1016/j.apsb.2021.12.021. Epub 2022 Jan 4. Acta Pharm Sin B. 2022. PMID: 35013704 Free PMC article. Review.
The successful clinical application of the lipid nanoparticle-based Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines highlights promising future of nanotechnology in vaccine development. ...In this review, we summarize the recent advances in vaccine nanotec …
The successful clinical application of the lipid nanoparticle-based Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines highlights pro …
Brain and behavior in health communication: The Canadian COVID-19 Experiences Project.
Hall PA, Fong GT, Hitchman SC, Quah ACK, Agar T, Meng G, Ayaz H, Dore BP, Sakib MN, Hudson A, Boudreau C. Hall PA, et al. Brain Behav Immun Health. 2022 Jul;22:100467. doi: 10.1016/j.bbih.2022.100467. Epub 2022 May 2. Brain Behav Immun Health. 2022. PMID: 35527791 Free PMC article.
BACKGROUND: Vaccine hesitancy and inconsistent mitigation behavior performance have been significant challenges throughout the COVID-19 pandemic. In Canada, despite relatively high vaccine availability and uptake, willingness to accept booster shots and maint …
BACKGROUND: Vaccine hesitancy and inconsistent mitigation behavior performance have been significant challenges throughout the COV
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine.
Shulman RM, Weinberg DS, Ross EA, Ruth K, Rall GF, Olszanski AJ, Helstrom J, Hall MJ, Judd J, Chen DYT, Uzzo RG, Dougherty TP, Williams R, Geynisman DM, Fang CY, Fisher RI, Strother M, Huelsmann E, Adige S, Whooley PD, Zarrabi K, Gupta B, Iyer P, McShane M, Yankey H, Lee CT, Burbure N, Laderman LE, Giurintano J, Reiss S, Horwitz EM. Shulman RM, et al. J Natl Compr Canc Netw. 2022 Feb;20(2):160-166. doi: 10.6004/jnccn.2021.7113. J Natl Compr Canc Netw. 2022. PMID: 35130494 Free PMC article.
Our objective was to record short-term adverse reactions to the COVID-19 vaccine in patients with cancer, to compare the magnitude and duration of these reactions with those of patients without cancer, and to determine whether adverse reactions are rel …
Our objective was to record short-term adverse reactions to the COVID-19 vaccine in patients with cancer, to compare th …
COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination.
Shah MR, Gabel A, Beers S, Salaru G, Lin Y, Cooper DL. Shah MR, et al. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e321-e326. doi: 10.1016/j.clml.2021.11.001. Epub 2021 Nov 11. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34872881 Free PMC article.
In this study, we examined antibody responses after complete COVID-19 vaccination in patients with plasma cell dyscrasias, most of whom were receiving treatment. ...CONCLUSIONS: Nearly all PCD had detectable anti-spike antibodies after vaccination but age, anti-CD38 monocl …
In this study, we examined antibody responses after complete COVID-19 vaccination in patients with plasma cell dyscrasias, most of wh …
Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study.
Kang W, Shami JJP, Yan VKC, Ye X, Blais JE, Li X, Lee VHF, Chui CSL, Lai FTT, Wan EYF, Wong CKH, Wong ICK, Chan EW. Kang W, et al. J Hematol Oncol. 2022 May 19;15(1):66. doi: 10.1186/s13045-022-01265-9. J Hematol Oncol. 2022. PMID: 35590336 Free PMC article.
BACKGROUND: The World Health Organization has defined a list of adverse events of special interest (AESI) for safety surveillance of vaccines. AESI have not been adequately assessed following COVID-19 vaccination in patients with cancer contributing to vaccine
BACKGROUND: The World Health Organization has defined a list of adverse events of special interest (AESI) for safety surveillance of vaccine …
Cancer staff in an NHS cancer center: infections, vaccination, stress and well-being support during the COVID-19 pandemic.
Hadi H, Handford J, Russell B, Moss CL, Monroy Iglesias MJ, Rammant E, Smith S, Dolly S, Thillai K, Rigg A, Hemelrijck MV. Hadi H, et al. Future Oncol. 2022 Jun;18(18):2201-2216. doi: 10.2217/fon-2022-0071. Epub 2022 Apr 6. Future Oncol. 2022. PMID: 35382557 Free PMC article.

Ethnicity (p = 0.020) and comorbidity burden (p = 0.022) were associated with SARS-CoV-2 infection status. Of 199 respondents, seven (3.6%) were vaccine-hesitant, which was associated with low flu vaccine uptake (p < 0.001). ...However, the impact for cancer

Ethnicity (p = 0.020) and comorbidity burden (p = 0.022) were associated with SARS-CoV-2 infection status. Of 199 respondents, seven (3.6%) …
Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors.
Konnova A, De Winter FHR, Gupta A, Verbruggen L, Hotterbeekx A, Berkell M, Teuwen LA, Vanhoutte G, Peeters B, Raats S, der Massen IV, De Keersmaecker S, Debie Y, Huizing M, Pannus P, Neven KY, Ariën KK, Martens GA, Bulcke MVD, Roelant E, Desombere I, Anguille S, Berneman Z, Goossens ME, Goossens H, Malhotra-Kumar S, Tacconelli E, Vandamme T, Peeters M, van Dam P, Kumar-Singh S. Konnova A, et al. Front Immunol. 2022 Dec 22;13:1062136. doi: 10.3389/fimmu.2022.1062136. eCollection 2022. Front Immunol. 2022. PMID: 36618384 Free PMC article.
BACKGROUND: Patients with cancer, especially hematological cancer, are at increased risk for breakthrough COVID-19 infection. So far, a predictive biomarker that can assess compromised vaccine-induced anti-SARS-CoV-2 immunity in cancer patients …
BACKGROUND: Patients with cancer, especially hematological cancer, are at increased risk for breakthrough COVID-19 infe …
Knowledge, Attitudes, and Practices of Healthcare Workers in Jordan towards the COVID-19 Vaccination.
Lataifeh L, Al-Ani A, Lataifeh I, Ammar K, AlOmary A, Al-Hammouri F, Al-Hussaini M. Lataifeh L, et al. Vaccines (Basel). 2022 Feb 9;10(2):263. doi: 10.3390/vaccines10020263. Vaccines (Basel). 2022. PMID: 35214721 Free PMC article.
The rapid development of COVID-19 vaccines raises concerns over vaccine hesitancy among healthcare workers (HCWs) and the general public, which made understanding the factors influencing hesitancy crucial in the maintenance of a solid healthcare system. ...A total o …
The rapid development of COVID-19 vaccines raises concerns over vaccine hesitancy among healthcare workers (HCWs) and the gene …
Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study.
McKeigue PM, McAllister DA, Hutchinson SJ, Robertson C, Stockton D, Colhoun HM. McKeigue PM, et al. Lancet Respir Med. 2022 Jun;10(6):566-572. doi: 10.1016/S2213-2600(22)00045-5. Epub 2022 Feb 25. Lancet Respir Med. 2022. PMID: 35227416 Free PMC article.
We aimed to investigate, for the two main classes of vaccine, whether efficacy against severe COVID-19 has decreased since delta became the predominant variant and whether the efficacy of two doses of vaccine against severe COVID-19 wanes with time sin …
We aimed to investigate, for the two main classes of vaccine, whether efficacy against severe COVID-19 has decreased since del …
Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases.
Poparn H, Srichumpuang C, Sosothikul D, Jantarabenjakul W, Lauhasurayotin S, Techavichit P, Chiangthong K, Poovorawan Y. Poparn H, et al. Asian Pac J Cancer Prev. 2022 Jun 1;23(6):2049-2055. doi: 10.31557/APJCP.2022.23.6.2049. Asian Pac J Cancer Prev. 2022. PMID: 35763647 Free PMC article.
BACKGROUND: The BNT162b2 mRNA COVID-19 vaccine has been administered to children and adolescents with cancer and hematologic diseases since they are at high risk of manifesting severe symptoms if they have COVID-19 infection but the adequate immune res …
BACKGROUND: The BNT162b2 mRNA COVID-19 vaccine has been administered to children and adolescents with cancer and hemato …
Assessing the Impact of Use and Trust in Different Sources of Information on COVID-19 Vaccination Uptake in Saudi Arabia (SA) Using the COVID-19 Vaccine Hesitancy and Resistance in SA (CoV-HERSA) Tool.
Sayed AA. Sayed AA. Trop Med Infect Dis. 2022 Nov 14;7(11):375. doi: 10.3390/tropicalmed7110375. Trop Med Infect Dis. 2022. PMID: 36422927 Free PMC article.
The COVID-19 Vaccine Hesitance and Resistance in SA (CoV-HERSA) tool was developed, validated, and distributed to 387 participants to accurately measure their COVID-19 vaccine hesitancy and its influencing factors. ...The CoV-HERSA is a validated tool …
The COVID-19 Vaccine Hesitance and Resistance in SA (CoV-HERSA) tool was developed, validated, and distributed to 387 particip …
SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand.
Ungtrakul T, Sornsamdang G, Soonklang K, Saeloo S, Wittayasak K, Suptawiwat O, Pulmanausahakul R, Phattraprayoon N, Auewarakul C, Mahanonda N. Ungtrakul T, et al. Public Health Pract (Oxf). 2022 Dec;4:100341. doi: 10.1016/j.puhip.2022.100341. Epub 2022 Nov 6. Public Health Pract (Oxf). 2022. PMID: 36373034 Free PMC article.
Low vaccine coverage in the early phase of the coronavirus disease 2019 (COVID-19) pandemic meant that personal and social measures to reduce viral spread were the only methods of lowering the risk of infection among cancer patients. This study explored the p …
Low vaccine coverage in the early phase of the coronavirus disease 2019 (COVID-19) pandemic meant that personal and social mea …
The Disease Influenced Vaccine Acceptance Scale-Six (DIVAS-6): Validation of a Measure to Assess Disease-Related COVID-19 Vaccine Attitudes and Concerns.
Grech L, Loe BS, Day D, Freeman D, Kwok A, Nguyen M, Bain N, Segelov E. Grech L, et al. Behav Med. 2022 Jun 15:1-10. doi: 10.1080/08964289.2022.2082358. Online ahead of print. Behav Med. 2022. PMID: 35703037
We developed a six-item scale assessing disease-related COVID-19 vaccine attitudes and concerns (The Disease Influenced COVID-19 Vaccine Acceptance Scale-Six: DIVAS-6). ...This is the first validated scale to measure disease-related COVID-19 …
We developed a six-item scale assessing disease-related COVID-19 vaccine attitudes and concerns (The Disease Influenced COV
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.
Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF. Rouhani SJ, et al. J Immunother Cancer. 2022 Jun;10(6):e004766. doi: 10.1136/jitc-2022-004766. J Immunother Cancer. 2022. PMID: 35732350 Free PMC article.
BACKGROUND: Patients with cancer were excluded from phase 3 COVID-19 vaccine trials, and the immunogenicity and side effect profiles of these vaccines in this population is not well understood. ...METHODS: Antibodies to the SARS-CoV-2 receptor binding domain …
BACKGROUND: Patients with cancer were excluded from phase 3 COVID-19 vaccine trials, and the immunogenicity and side ef …
Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis.
Yin J, Chen Y, Li Y, Zhang X, Wang C. Yin J, et al. Hum Vaccin Immunother. 2022 Nov 30;18(6):2119763. doi: 10.1080/21645515.2022.2119763. Epub 2022 Sep 26. Hum Vaccin Immunother. 2022. PMID: 36161976 Free PMC article.
Patients with solid cancer have an increased risk of severe coronavirus disease 2019 (COVID-19) and associated mortality than the general population. This meta-analysis aimed to investigate the currently available evidence about the efficacy of COVID-19 vacci …
Patients with solid cancer have an increased risk of severe coronavirus disease 2019 (COVID-19) and associated mortality than …
Black-and-white thinking and conspiracy beliefs prevent parents from vaccinating their children against COVID-19.
Iannello P, Colautti L, Magenes S, Antonietti A, Cancer A. Iannello P, et al. Appl Cogn Psychol. 2022 Sep 21:10.1002/acp.3999. doi: 10.1002/acp.3999. Online ahead of print. Appl Cogn Psychol. 2022. PMID: 36250193 Free PMC article.
Understanding predictors of parents' willingness to vaccinate their children appears fundamental to promote vaccine acceptability, especially in a pandemic scenario. The present study aimed to investigate the role of conspiracy beliefs and absolutist thinking in parental a …
Understanding predictors of parents' willingness to vaccinate their children appears fundamental to promote vaccine acceptability, es …
Investigation of anxiety sensitivity levels of cancer patients in terms of COVID-19 vaccine: a cross-sectional study.
Iscan G, Cetin B, Kilic F, Kalayci H, Kalayci A, Iscan SC. Iscan G, et al. Support Care Cancer. 2022 May;30(5):4139-4147. doi: 10.1007/s00520-021-06750-4. Epub 2022 Jan 24. Support Care Cancer. 2022. PMID: 35067730 Free PMC article.
INTRODUCTION: Our study's purpose was to investigate the viewpoints of cancer patients who had not yet been vaccinated. Cancer patients usually cannot get every vaccine because their immunity is low. ...We discovered that 79.1% (n = 408) of respondents were n …
INTRODUCTION: Our study's purpose was to investigate the viewpoints of cancer patients who had not yet been vaccinated. Cancer
Was EU's COVID-19 vaccine procurement strategy irrational? A re-analysis based on cost-effectiveness considerations.
Gandjour A. Gandjour A. BMC Health Serv Res. 2022 Nov 24;22(1):1410. doi: 10.1186/s12913-022-08726-4. BMC Health Serv Res. 2022. PMID: 36434631 Free PMC article.
AIM: The European Union (EU) has received criticism for being slow to secure coronavirus disease (COVID-19) vaccine contracts in 2020 before the approval of the first COVID-19 vaccine. ...RESULTS: A vaccine with 50% efficacy against death due to …
AIM: The European Union (EU) has received criticism for being slow to secure coronavirus disease (COVID-19) vaccine contracts …
Medical Mistrust, Perceived Discrimination, and Race: a Longitudinal Analysis of Predictors of COVID-19 Vaccine Hesitancy in US Adults.
Morgan KM, Maglalang DD, Monnig MA, Ahluwalia JS, Avila JC, Sokolovsky AW. Morgan KM, et al. J Racial Ethn Health Disparities. 2022 Aug 1:1-10. doi: 10.1007/s40615-022-01368-6. Online ahead of print. J Racial Ethn Health Disparities. 2022. PMID: 35913543 Free PMC article.
First, we examined whether race and ethnicity, perceived discrimination, medical mistrust, and other demographic factors were predictors of COVID-19 vaccine hesitancy and vaccine behavior. Second, we sought to assess whether medical mistrust and perceived dis …
First, we examined whether race and ethnicity, perceived discrimination, medical mistrust, and other demographic factors were predictors of …
Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people.
Parry H, Bruton R, Ayodele R, Sylla P, McIlroy G, Logan N, Scott S, Nicol S, Verma K, Stephens C, Willett B, Zuo J, Moss P. Parry H, et al. Cell Rep Med. 2022 Sep 20;3(9):100739. doi: 10.1016/j.xcrm.2022.100739. Epub 2022 Aug 25. Cell Rep Med. 2022. PMID: 36075216 Free PMC article.
Age is the strongest determinant of COVID-19 mortality, and over 2 billion people have received primary series vaccination with BNT162b2 (mRNA) or ChAdOx1 (adenoviral vector). However, the profile of sustained vaccine immunogenicity in older people is unknown. Here, …
Age is the strongest determinant of COVID-19 mortality, and over 2 billion people have received primary series vaccination with BNT16 …
Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls.
Pakvisal N, Sainamthip P, Teeyapun N, Luangdilok S, Wanlapakorn N, Yorsaeng R, Poovorawan Y, Pakvisal P, Susiriwatananont T, Zungsontiporn N, Sriuranpong V, Tanasanvimon S, Wanchaijiraboon P. Pakvisal N, et al. Hum Vaccin Immunother. 2022 Nov 30;18(6):2094149. doi: 10.1080/21645515.2022.2094149. Epub 2022 Jul 1. Hum Vaccin Immunother. 2022. PMID: 35776836 Free PMC article.
The study aimed to evaluate vaccine-related adverse events (VRAEs) following ChAdOx1-nCoV-19 vaccine in solid cancer patients receiving treatment compared to healthy controls. 399 cancer patients and 90 healthy volunteers were enrolled. ...In summary, …
The study aimed to evaluate vaccine-related adverse events (VRAEs) following ChAdOx1-nCoV-19 vaccine in solid cancer pa …
Combined Effects of Exercise Training and Nutritional Supplementation in Cancer Patients in the Context of the COVID-19: A Perspective Study.
Molanouri Shamsi M, Vahed A, Hekmatikar AA, Suzuki K. Molanouri Shamsi M, et al. Front Nutr. 2022 Mar 9;9:847215. doi: 10.3389/fnut.2022.847215. eCollection 2022. Front Nutr. 2022. PMID: 35356739 Free PMC article.
Many risk factors have been identified in the progression of COVID-19 to severe and critical stages, and it is shown that the coronavirus appears more severely in people with cancer. ...Using lifestyle strategies such as regular physical activity and intake of funct …
Many risk factors have been identified in the progression of COVID-19 to severe and critical stages, and it is shown that the coronav …
Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.
Morales-Núñez JJ, Muñoz-Valle JF, Machado-Sulbarán AC, Díaz-Pérez SA, Torres-Hernández PC, Panduro-Espinoza BV, Gallegos-Díaz de Leon JA, Munguía-Ramirez CD, Hernández-Bello J. Morales-Núñez JJ, et al. Immunol Lett. 2022 Dec;251-252:20-28. doi: 10.1016/j.imlet.2022.10.002. Epub 2022 Oct 21. Immunol Lett. 2022. PMID: 36279685 Free PMC article.
Neutralizing antibodies (NAbs) can be indicators of collective immunity, vaccine efficacy, and the longevity of the humoral response. This study aimed to compare reactogenicity and NAbs generated by three different COVID-19 vaccine platforms in individuals wi …
Neutralizing antibodies (NAbs) can be indicators of collective immunity, vaccine efficacy, and the longevity of the humoral response. …
The Current Landscape of mRNA Vaccines Against Viruses and Cancer-A Mini Review.
Ladak RJ, He AJ, Huang YH, Ding Y. Ladak RJ, et al. Front Immunol. 2022 May 6;13:885371. doi: 10.3389/fimmu.2022.885371. eCollection 2022. Front Immunol. 2022. PMID: 35603213 Free PMC article. Review.
Both infectious viral diseases and cancer have historically been some of the most common causes of death worldwide. The COVID-19 pandemic is a decidedly relevant example of the former. ...
Both infectious viral diseases and cancer have historically been some of the most common causes of death worldwide. The COVID- …
COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study.
Nguyen M, Bain N, Grech L, Choi T, Harris S, Chau H, Freeman D, Kwok A, Williams J, McCartney A, Webber K, Day D, Segelov E. Nguyen M, et al. Asia Pac J Clin Oncol. 2022 Dec;18(6):570-577. doi: 10.1111/ajco.13754. Epub 2022 Jan 18. Asia Pac J Clin Oncol. 2022. PMID: 35043559
INTRODUCTION: People with cancer are at higher risk of serious illness and death from COVID-19 infection. ...Vaccine hesitancy was measured by the validated Oxford COVID-19 vaccine hesitancy scale. ...
INTRODUCTION: People with cancer are at higher risk of serious illness and death from COVID-19 infection. ...Vaccine he …
16 Months Follow Up of Patients' Behavior and Mild COVID-19 Patterns in a Large Cohort of Cancer Patients During the Pandemic.
Hajjaji N, Lepoutre K, Lakhdar S, Bécourt S, Bellier C, Kaczmarek E, Broyelle A, Giscard S, Lartigau E. Hajjaji N, et al. Front Oncol. 2022 Jun 7;12:901426. doi: 10.3389/fonc.2022.901426. eCollection 2022. Front Oncol. 2022. PMID: 35747798 Free PMC article.
Background: Acute severe forms of COVID-19 infection are more likely in cancer patients and growing attention has been given to the persistent symptoms of the disease after severe COVID-19. However, mild illness is the dominant clinical presentation of COV
Background: Acute severe forms of COVID-19 infection are more likely in cancer patients and growing attention has been given t …
A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
Joudi M, Moradi Binabaj M, Porouhan P, PeyroShabany B, Tabasi M, Fazilat-Panah D, Khajeh M, Mehrabian A, Dehghani M, Welsh JS, Keykhosravi B, Akbari Yazdi A, Ariamanesh M, Ghasemi A, Ferns G, Javadinia SA. Joudi M, et al. Front Endocrinol (Lausanne). 2022 Mar 1;13:798975. doi: 10.3389/fendo.2022.798975. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35299966 Free PMC article.
AIM: To determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer. METHODS: In this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 11.5 years old) were assessed …
AIM: To determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer. METHO …
Sinopharm's BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2.
Abdelhafiz AS, Ali A, Kamel MM, Ahmed EH, Sayed DM, Bakry RM. Abdelhafiz AS, et al. Vaccines (Basel). 2022 Sep 3;10(9):1462. doi: 10.3390/vaccines10091462. Vaccines (Basel). 2022. PMID: 36146540 Free PMC article.
Of the 109 recruited subjects, 60 (55%) received the ChAdOx1 nCoV-19 vaccine, and the remainder received the BBIBP-CorV vaccine. The total antibody level did not significantly differ between the two groups. ...None of the participants were admitted to the hospital o …
Of the 109 recruited subjects, 60 (55%) received the ChAdOx1 nCoV-19 vaccine, and the remainder received the BBIBP-CorV vaccine
Serological response to a third booster dose of BNT162b2 COVID-19 vaccine among seronegative cancer patients.
Shmueli ES, Lawrence YR, Rahav G, Itay A, Lustig Y, Halpern N, Boursi B, Margalit O. Shmueli ES, et al. Cancer Rep (Hoboken). 2022 Aug;5(8):e1645. doi: 10.1002/cnr2.1645. Epub 2022 Jun 2. Cancer Rep (Hoboken). 2022. PMID: 35652556 Free PMC article.
BACKGROUND AND AIM: The BNT162b2 COVID-19 vaccine (Pfizer/BioNTech), given as a two-dose series, 3 weeks apart, elicits a serological response in 84-98% of patients with cancer, even if administered while undergoing anticancer treatments. Herein, we report th …
BACKGROUND AND AIM: The BNT162b2 COVID-19 vaccine (Pfizer/BioNTech), given as a two-dose series, 3 weeks apart, elicits a sero …
The impact of COVID-19 on income and employment and willingness to become vaccinated among African Americans enrolled in a smoking cessation randomized trial.
Cruvinel E, P Richter K, S Scheuermann T, M Machado N, Mayo MS, R Brown A, L Nollen N. Cruvinel E, et al. Vaccine. 2022 Mar 15;40(12):1712-1716. doi: 10.1016/j.vaccine.2022.01.064. Epub 2022 Feb 7. Vaccine. 2022. PMID: 35168840 Free PMC article. Clinical Trial.
Given vulnerability to COVID-19 among smokers and vaccine hesitancy among populations disproportionately burdened with COVID-19, it's important to understand concerns about vaccines and the impact of COVID-19 on these subgroups. ...Most, 103 (64.4%), w …
Given vulnerability to COVID-19 among smokers and vaccine hesitancy among populations disproportionately burdened with COVI
Moral Foundations Predict COVID-19 Vaccine Hesitancy: Evidence from a National Survey of Black Americans.
Nan X, Wang Y, Thier K, Adebamowo C, Quinn S, Ntiri S. Nan X, et al. J Health Commun. 2022 Dec 28:1-11. doi: 10.1080/10810730.2022.2160526. Online ahead of print. J Health Commun. 2022. PMID: 36576158
In this study we examine the role of moral values in predicting COVID-19 vaccine hesitancy among Black Americans. Guided by moral foundations theory, we assess the associations between six moral foundations (care, fairness, loyalty, authority, purity, liberty) and a …
In this study we examine the role of moral values in predicting COVID-19 vaccine hesitancy among Black Americans. Guided by mo …
Vaccine-Related Lymph Nodes: The Emerging Pitfalls of 18F-Fluorocholine and 68Ga-PSMA-11 PET/CT in the Era of COVID-19 Vaccination.
Ah-Thiane L, Ferrer L, Maucherat B, Fleury V, Le Thiec M, Rusu D, Rousseau C. Ah-Thiane L, et al. Clin Nucl Med. 2022 Jul 1;47(7):575-582. doi: 10.1097/RLU.0000000000004190. Epub 2022 Apr 27. Clin Nucl Med. 2022. PMID: 35675134 Free PMC article.
PATIENTS AND METHODS: Between February and July 2021, all consecutive patients undergoing a whole-body PET/CT for any indication using a different radiopharmaceutical from 18F-FDG were eligible for inclusion if they had received at least 1 dose of the COVID-19 vaccine
PATIENTS AND METHODS: Between February and July 2021, all consecutive patients undergoing a whole-body PET/CT for any indication using a dif …
Spontaneous tumor regression following COVID-19 vaccination.
Sousa LG, McGrail DJ, Li K, Marques-Piubelli ML, Gonzalez C, Dai H, Ferri-Borgogno S, Godoy M, Burks J, Lin SY, Bell D, Ferrarotto R. Sousa LG, et al. J Immunother Cancer. 2022 Mar;10(3):e004371. doi: 10.1136/jitc-2021-004371. J Immunother Cancer. 2022. PMID: 35241495 Free PMC article.
Vaccination against COVID-19 is critical for immuno-compromised individuals, including patients with cancer. ...Insight: This case suggests that the mRNA-1273 COVID-19 vaccine stimulated anticancer immunity and tumor regression....
Vaccination against COVID-19 is critical for immuno-compromised individuals, including patients with cancer. ...Insight: This …
COVID-19 vaccine hesitancy among different population groups in China: a national multicenter online survey.
Huang Y, Su X, Xiao W, Wang H, Si M, Wang W, Gu X, Ma L, Li L, Zhang S, Yang C, Yu Y, Qiao Y. Huang Y, et al. BMC Infect Dis. 2022 Feb 14;22(1):153. doi: 10.1186/s12879-022-07111-0. BMC Infect Dis. 2022. PMID: 35164700 Free PMC article.
The questionnaire contained sociodemographic information, concerns about infection with COVID-19, general vaccination behaviors and attitudes, the General Vaccine Hesitancy Scale, the COVID-19 Vaccine Hesitancy Scale and other potential factors. ...Whi …
The questionnaire contained sociodemographic information, concerns about infection with COVID-19, general vaccination behaviors and a …